(dp1
S'10.1016/j.ijid.2006.09.010'
p2
(lp3
S'nasal vaccine candidate'
p4
aS'nasal vaccine'
p5
aS'healthy adults'
p6
aS'adverse events were'
p7
aS'7 15 30'
p8
aS'30 and 60'
p9
aS'0 7 15'
p10
aS'Adverse events were'
p11
aS'nasal'
p12
aS'trial'
p13
aS'HBsAg and HBcAg'
p14
aS'hepatitis B virus'
p15
aS'data collection sheets'
p16
aS'placebo group'
p17
aS'anti HBc antibodies'
p18
aS'30 days after'
p19
aS'anti HBs antibody'
p20
asS'10.1016/j.jada.2006.08.007'
p21
(lp22
S'gestational weight gain'
p23
aS'excessive gestational weight'
p24
aS'prenatal nutrition interventions'
p25
aS'inadequate and excessive'
p26
aS'Social Cognitive Theory'
p27
aS'excessive gestational'
p28
aS'education and counseling'
p29
aS'appropriate gestational weight'
p30
aS'Institute of Medicine'
p31
aS'both inadequate'
p32
aS'among pregnant adolescents'
p33
aS'nutrition education'
p34
aS'uoi B758G 4M9NHJD'
p35
aS'prenatal nutrition'
p36
aS'among pregnant teens'
p37
aS'effect on birth'
p38
aS'highest risk'
p39
asS'10.1016/j.clinthera.2006.05.008'
p40
(lp41
S'6 month'
p42
aS'blind placebo controlled'
p43
aS'randomized double blind'
p44
aS'month randomized double'
p45
aS'double blind placebo'
p46
aS'6 month randomized'
p47
aS'sibutramine in obese'
p48
aS'sibutramine'
p49
aS'sibutramine group'
p50
aS'group at end'
p51
aS'placebo group'
p52
aS'obese Mexican adolescents'
p53
aS'placebo'
p54
aS'diet and exercise'
p55
aS'05 for all'
p56
aS'sibutramine group changed'
p57
aS'2 95 CI'
p58
asS'10.1037/0003-066X.33.9.821'
p59
(lp60
S'psychotherapy research'
p61
aS'psychotherapy'
p62
aS'need to control'
p63
aS'authors suggest'
p64
aS'placebo'
p65
aS'inert procedure without'
p66
aS'control for such'
p67
aS'ref PsycINFO Database'
p68
aS'available therapies component'
p69
aS'placebo effect rubric'
p70
aS'condition being treated'
p71
aS'without specific activity'
p72
aS'contact and therapist'
p73
aS'term placebo group'
p74
aS'controls in psychotherapy'
p75
aS'discussed 26 ref'
p76
aS'psychotherapy placebo group'
p77
asS'10.1016/S0002-8223(95)00279-0'
p78
(lp79
S'receiving nutrition advice'
p80
aS'prenatal care'
p81
aS'mothers reported receiving'
p82
aS'Live Birth File'
p83
aS'advice by maternal'
p84
aS'Infant Death File'
p85
aS'breast feeding'
p86
aS'prenatal'
p87
aS'mothers receiving'
p88
aS'among live births'
p89
aS'maternal characteristics among'
p90
aS'Table 1 Percent'
p91
aS'n 9 639'
p92
aS'mothers receiving nutrition'
p93
aS'characteristics among live'
p94
aS'weighted of mothers'
p95
aS'1 Percent weighted'
p96
asS'10.1016/S0188-4409(03)00069-9'
p97
(lp98
S'body fat pattern'
p99
aS'low income'
p100
aS'incidence and progression'
p101
aS'body fat'
p102
aS'grade 1 obesity'
p103
aS'overweight and obesity'
p104
aS'body mass index'
p105
aS'progression of obesity'
p106
aS'Mexico'
p107
aS'first follow up'
p108
aS'obesity'
p109
aS'mean waist circumference'
p110
aS'follow up phases'
p111
aS'Mexico City'
p112
aS'fat pattern distribution'
p113
aS'Mexican population'
p114
aS'99 70 44'
p115
asS'd'
(lp116
S'nasal vaccine candidate'
p117
aS'nasal vaccine'
p118
aS'healthy adults'
p119
aS'adverse events were'
p120
aS'7 15 30'
p121
aS'30 and 60'
p122
aS'0 7 15'
p123
aS'Adverse events were'
p124
aS'nasal'
p125
aS'trial'
p126
aS'HBsAg and HBcAg'
p127
aS'hepatitis B virus'
p128
aS'data collection sheets'
p129
aS'placebo group'
p130
aS'anti HBc antibodies'
p131
aS'30 days after'
p132
aS'anti HBs antibody'
p133
aS'50 g HBcAg'
p134
aS'50 g HBsAg'
p135
aS'Source data collection'
p136
aS'healthy'
p137
aS'day 30'
p138
aS'trial in healthy'
p139
aS'core antigens'
p140
aS'seroconversion in 100'
p141
aS'proportion of subjects'
p142
aS'vaccine'
p143
aS'HBsAg HBcAg vaccine'
p144
aS'HBcAg vaccine candidate'
p145
aS'60 days'
p146
aS'day 90 75'
p147
aS'HBs and anti'
p148
aS'9 8 palate'
p149
aS'9 8 headache'
p150
aS'34 1 rhinorrhea'
p151
aS'included sneezing 34'
p152
aS'8 palate itching'
p153
aS'2 nasal stuffiness'
p154
aS'12 2 nasal'
p155
aS'1 rhinorrhea 12'
p156
aS'mild in intensity'
p157
aS'events were recorded'
p158
aS'were recorded during'
p159
aS'anti HBc'
p160
aS'study'
p161
aS'anti HBc seroconversion'
p162
aS'well tolerated'
p163
aS'nasal route'
p164
aS'12h 24h 48h'
p165
aS'24h 48h 72h'
p166
aS'6h 12h 24h'
p167
aS'events were actively'
p168
aS'were actively recorded'
p169
aS'via nasal spray'
p170
aS'hepatitis B vaccine'
p171
aS'19 healthy male'
p172
aS'were randomly allocated'
p173
aS'systemic adverse events'
p174
aS'healthy male adults'
p175
aS'physiologic saline solution'
p176
aS'day 90'
p177
aS'CIGB Havana Cuba'
p178
aS'nasal co administration'
p179
aS'immunization schedule'
p180
aS'placebo'
p181
aS'HBs antibody levels'
p182
aS'Source data'
p183
aS'first'
p184
aS'B virus HBV'
p185
aS'safety and immunogenicity'
p186
aS'events were defined'
p187
aS'local adverse events'
p188
aS'events were reported'
p189
aS'clinical trial'
p190
aS'50'
p191
aS'responders anti HBs'
p192
aS'total'
p193
aS'day'
p194
aS'HBsAg HBcAg'
p195
aS'hepatitis B vaccines'
p196
aS'Center for Genetic'
p197
aS'Genetic Engineering Biotechnology'
p198
aS'strong immunogenicity'
p199
aS'clinical'
p200
aS'HBcAg and HBsAg'
p201
aS'45 years'
p202
aS'immunogenicity of HBcAg'
p203
aS'HBcAg'
p204
aS'route with 50'
p205
aS'g HBsAg following'
p206
aS'linked to 50'
p207
aS'HBcAg HBsAg vaccine'
p208
aS'response to HBcAg'
p209
aS'HBsAg vaccine candidate'
p210
aS'HBcAg non covalently'
p211
aS'candidate in healthy'
p212
aS'healthy volunteers immunized'
p213
aS'phase'
p214
aS'Center for Toxicology'
p215
aS'J Finlay Hospital'
p216
aS'Carlos J Finlay'
p217
aS'doses per study'
p218
aS'Frequency of each'
p219
aS'number of applied'
p220
aS'applied doses per'
p221
aS'per study group'
p222
aS'event with respect'
p223
aS'type of adverse'
p224
aS'well'
p225
aS'60'
p226
aS'severe'
p227
aS'vaccine candidate'
p228
aS'hepatitis'
p229
aS'vaccine recipients'
p230
aS'chronic'
p231
aS'nasal wash'
p232
aS'0 5ml'
p233
aS'chronic HBV infected'
p234
aS'19 healthy'
p235
aS'any'
p236
aS'World Health Organization'
p237
aS'results'
p238
aS'nasal co'
p239
aS'HBsAg'
p240
aS'subjects'
p241
aS'systemic adverse'
p242
aS'any other'
p243
aS'written informed consent'
p244
aS'immunization'
p245
aS'mice'
p246
aS'chronic infection'
p247
aS'adverse event'
p248
aS'other'
p249
aS'two'
p250
aS'vaccine group'
p251
aS'anti HBs'
p252
aS'Genetic Engineering'
p253
aS'chronic HBV'
p254
aS'volunteers'
p255
aS'immunogenic'
p256
aS'mixture of 50'
p257
aS'axillary temperature'
p258
aS'core'
p259
aS'immunity'
p260
aS'more than'
p261
aS'general malaise'
p262
aS'30 days'
p263
aS'systemic'
p264
aS'100'
p265
aS'systemic immunity'
p266
aS'anti'
p267
aS'each'
p268
aS'local adverse'
p269
aS'animal'
p270
aS'full length'
p271
aS'knowledge'
p272
aS'anti HBs titers'
p273
aS'events were mild'
p274
aS'safe'
p275
aS'applied doses'
p276
aS'placebo group withdrew'
p277
aS'study group'
p278
aS'virus'
p279
aS'patients with chronic'
p280
aS'intensity'
p281
aS'candidate comprising HBV'
p282
aS'study in healthy'
p283
aS'demonstration of safety'
p284
aS'safe well tolerated'
p285
aS'comprising HBV antigens'
p286
aS'tolerated and immunogenic'
p287
aS'vaccine candidate comprising'
p288
aS'unexpected events were'
p289
aS'using corresponding ELISA'
p290
aS'vaccine elicited anti'
p291
aS'tolerated Adverse reactions'
p292
aS'seroprotective anti HBs'
p293
aS'well tolerated Adverse'
p294
aS'dose Anti HBs'
p295
aS'elicited anti HBc'
p296
aS'each dose Anti'
p297
aS'after each dose'
p298
aS'titers were evaluated'
p299
aS'severe or unexpected'
p300
aS'reactions included sneezing'
p301
aS'per nostril Adverse'
p302
aS'early as day'
p303
aS'kits at days'
p304
aS'1h 6h 12h'
p305
aS'anti HBc titers'
p306
aS'recorded 1h 6h'
p307
aS'immunization schedule while'
p308
aS'100 of subjects'
p309
aS'were evaluated using'
p310
aS'nostril Adverse events'
p311
aS'actively recorded 1h'
p312
aS'evaluated using corresponding'
p313
aS'intensity No severe'
p314
aS'corresponding ELISA kits'
p315
aS'HBs titer 10IU'
p316
aS'days and 30'
p317
aS'days after each'
p318
aS'HBc titers were'
p319
aS'safe and well'
p320
aS'75 All subjects'
p321
aS'subjects as early'
p322
aS'placebo group remained'
p323
aS'30 and 90'
p324
aS'72h 7 days'
p325
aS'90 75 All'
p326
aS'8 and general'
p327
aS'group remained seronegative'
p328
aS'remained seronegative during'
p329
aS'maximum at day'
p330
aS'anti HBs titer'
p331
aS'limiting and mild'
p332
aS'reactions were all'
p333
aS'were all self'
p334
aS'all self limiting'
p335
aS'Adverse reactions included'
p336
aS'placebo via nasal'
p337
aS'five dose schedule'
p338
aS'administered in two'
p339
aS'0 9 physiologic'
p340
aS'9 physiologic saline'
p341
aS'NASVAC comprising hepatitis'
p342
aS'vaccine candidate NASVAC'
p343
aS'HBV surface HBsAg'
p344
aS'double blinded placebo'
p345
aS'profile of nasal'
p346
aS'safety and immunogenic'
p347
aS'candidate NASVAC comprising'
p348
aS'core antigens HBcAg'
p349
aS'HBV recombinant antigens'
p350
aS'administration of both'
p351
aS'randomized clinical trial'
p352
aS'markers of immunity'
p353
aS'both HBV recombinant'
p354
aS'according to Good'
p355
aS'guidelines Participants ranged'
p356
aS'immunogenic in animal'
p357
aS'HBsAg and core'
p358
aS'18 to 45'
p359
aS'infection to HBV'
p360
aS'aimed at exploring'
p361
aS'years and were'
p362
aS'allocated to receive'
p363
aS'Practice guidelines Participants'
p364
aS'Good Clinical Practice'
p365
aS'placebo controlled randomized'
p366
aS'ranged in age'
p367
aS'Clinical Practice guidelines'
p368
aS'blinded placebo controlled'
p369
aS'age from 18'
p370
aS'controlled randomized clinical'
p371
aS'virus HBV surface'
p372
aS'Source'
p373
aS'pre and post'
p374
aS'saliva and nasal'
p375
aS'nasal wash samples'
p376
aS'anterior and posterior'
p377
aS'covalently linked'
p378
aS'HBcAg HBsAg'
p379
aS'Antibody response'
p380
aS'healthy volunteers'
p381
aS'National Center'
p382
aS'Accuspray Becton Dickinson'
p383
aS'five'
p384
aS'full length HBcAg'
p385
aS'19'
p386
aS'each type'
p387
aS'total number'
p388
aS'concentration of anti'
p389
aS'reactions were'
p390
aS'more than 10IU'
p391
aS's exact test'
p392
aS'Fisher s exact'
p393
aS'also'
p394
aS'both'
p395
aS'early'
p396
aS'mean anti HBs'
p397
aS'confidence intervals were'
p398
aS'95 confidence intervals'
p399
aS'adverse events included'
p400
aS'linked immunosorbent assay'
p401
aS'enzyme linked immunosorbent'
p402
aS'C and any'
p403
aS'require medical attention'
p404
aS'may require medical'
p405
aS'combined to give'
p406
aS'age'
p407
aS'recombinant'
p408
aS'strong'
p409
aS'adverse events'
p410
aS'administered'
p411
aS'performed'
p412
aS'seroprotective'
p413
aS'respect'
p414
aS'administration'
p415
aS'studied'
p416
aS'mucosal'
p417
aS'unexpected'
p418
aS'patients'
p419
aS'saliva'
p420
aS'double blinded'
p421
aS'approximately'
p422
aS'were randomly'
p423
aS'adverse'
p424
aS'dose schedule'
p425
aS'World Health'
p426
aS'used'
p427
aS'time'
p428
aS'related'
p429
aS'HBV'
p430
aS'participants'
p431
aS'safety'
p432
aS'had'
p433
aS'45'
p434
aS'90'
p435
aS'local'
p436
aS'HBV antigens'
p437
aS'Phase'
p438
aS'most'
p439
aS'first inoculation'
p440
aS'nasal spray'
p441
aS'mixture'
p442
aS'more'
p443
aS'infected patients'
p444
aS'co'
p445
aS'immunogenicity'
p446
aS'populations'
p447
aS'control'
p448
aS'Genetic'
p449
aS'antiviral'
p450
aS'schedule'
p451
aS'addition'
p452
aS'nasal mucosa'
p453
aS'carried'
p454
aS'adults'
p455
aS'dose'
p456
aS'second'
p457
aS'immune'
p458
aS'post immunization'
p459
aS'access'
p460
aS'immune system'
p461
aS'second dose'
p462
aS'Center'
p463
aS'geometric mean'
p464
aS'further'
p465
aS'antigens'
p466
aS'Preclinical'
p467
aS'antibody responses'
p468
aS'relevant'
p469
aS'recorded during'
p470
aS'demonstrated'
p471
aS'vaccine formulation'
p472
aS'devices'
p473
aS'self'
p474
aS'general'
p475
aS'proportion'
p476
aS'serum'
p477
aS'T cell'
p478
aS'study prior'
p479
aS'all'
p480
aS'Figure'
p481
aS'antigen'
p482
aS'days'
p483
aS'full'
p484
aS'detection'
p485
aS'high'
p486
aS'subjects reporting'
p487
aS'18'
p488
aS'mild'
p489
aS'safe well'
p490
aS'first demonstration'
p491
aS'vaccine elicited'
p492
aS'seroprotective anti'
p493
aS'unexpected events'
p494
aS'days 30'
p495
aS'placebo via'
p496
aS'five dose'
p497
aS'two dosages'
p498
aS'total volume'
p499
aS'highly immunogenic'
p500
aS'serologic markers'
p501
aS'immunity infection'
p502
aS'animal models'
p503
aS'performed according'
p504
aS'immunogenic profile'
p505
aS'both HBV'
p506
aS'Good Clinical'
p507
aS'applied'
p508
aS'covalently'
p509
aS'Antibody'
p510
aS'National'
p511
aS'Toxicology'
p512
aS'Carlos'
p513
aS'Anti HBc'
p514
aS'experiments'
p515
aS'immunity against'
p516
aS'95'
p517
aS'Frequency'
p518
aS'participants inoculated'
p519
aS'purified'
p520
aS'were'
p521
aS'data collection'
p522
aS'other nasal'
p523
aS'study nurse'
p524
aS'order'
p525
aS'vaccine were'
p526
aS'shown'
p527
aS'95 confidence'
p528
aS'EM analysis'
p529
aS'development'
p530
aS'sensitivity'
p531
aS'carriers'
p532
aS'single'
p533
aS'responders'
p534
aS'infected'
p535
aS'commercial'
p536
aS'30'
p537
aS'formulation'
p538
aS'75'
p539
aS'Anti'
p540
aS'each dose'
p541
aS'protein'
p542
aS'screening'
p543
aS'reactions'
p544
aS'combined'
p545
aS'Havana'
p546
aS'15'
p547
aS'fourth'
p548
aS'Th1'
p549
aS'same'
p550
aS'7 days'
p551
aS'6h 12h'
p552
aS'undertaken'
p553
aS'axillary'
p554
aS'events'
p555
aS'third'
p556
aS'group'
p557
aS'antibody'
p558
aS'required'
p559
aS'negative'
p560
aS'6h'
p561
aS'need'
p562
aS'increase'
p563
aS'World'
p564
aS'infection'
p565
aS'licensed hepatitis'
p566
aS'double'
p567
aS'frequency'
p568
aS'72h'
p569
aS'headache'
p570
aS'recombinant HBcAg'
p571
aS'All'
p572
aS'sneezing'
p573
aS'achieved'
p574
aS'very'
p575
aS'all participants'
p576
aS'candidate'
p577
aS'one'
p578
aS'induced'
p579
aS'Cuba'
p580
aS'participants were'
p581
aS'reported'
p582
aS'spray'
p583
aS'evaluated'
p584
aS'hematology'
p585
aS'primary'
p586
aS'recorded'
p587
aS'potential'
p588
aS'positive'
p589
aS'elicited'
p590
aS'events were'
p591
aS'tolerated'
p592
aS'revealed'
p593
aS'samples'
p594
aS'licensed'
p595
aS'staff'
p596
aS'device'
p597
aS'data'
p598
aS'collection'
p599
aS'written informed'
p600
aS'recording'
p601
aS'use'
p602
aS'125'
p603
aS'EM'
p604
aS'analysis'
p605
aS'sera'
p606
aS'10IU'
p607
aS'baseline'
p608
aS'successive'
p609
aS'route'
p610
aS'HBc'
p611
aS'HBs'
p612
aS'titers'
p613
aS'developed'
p614
aS'blinded'
p615
aS'blood'
p616
aS'seroprotection'
p617
aS'after'
p618
aS'profile'
p619
aS'days after'
p620
aS'15 30'
p621
aS'7 15'
p622
aS'seroconversion'
p623
aS'vaccines'
p624
aS'B vaccines'
p625
aS'according'
p626
aS'using'
p627
aS'against'
p628
aS'against HBV'
p629
aS'HBV infection'
p630
aS'hypo'
p631
aS'Engineering'
p632
aS'Engineering Biotechnology'
p633
aS'Biotechnology'
p634
aS'volunteer'
p635
aS'nasal adverse'
p636
aS'than'
p637
aS'type'
p638
aS'HBcAg vaccine'
p639
aS'response'
p640
aS'commercial anti'
p641
aS'subjects were'
p642
aS'10'
p643
aS'Adverse'
p644
aS'Adverse events'
p645
aS'rhinorrhea'
p646
aS'stuffiness'
p647
aS'nasal stuffiness'
p648
aS'itching'
p649
aS'palate itching'
p650
aS'palate'
p651
aS'considered'
p652
aS'studies'
p653
aS'abnormalities'
p654
aS'responses against'
p655
aS'responses'
p656
aS'clinically'
p657
aS'self limiting'
p658
aS'limiting'
p659
aS'obtained'
p660
aS'without'
p661
aS'treatment'
p662
aS'planned'
p663
aS'observation period'
p664
aS'doses'
p665
aS'titer'
p666
aS'remained'
p667
aS'group remained'
p668
aS'surface'
p669
aS'system'
p670
aS'present'
p671
aS'geometric'
p672
aS'90 75'
p673
aS'inoculation'
p674
aS'specific'
p675
aS'were mild'
p676
aS'per'
p677
aS'Havana Cuba'
p678
aS'post'
p679
aS'hyper responder'
p680
aS'basic'
p681
aS'g HBcAg'
p682
aS'g HBsAg'
p683
aS'12h'
p684
aS'Participants'
p685
aS'corresponding'
p686
aS'resulted'
p687
aS'event'
p688
aS'during'
p689
aS'seronegative'
p690
aS'standard'
p691
aS'enough'
p692
aS'included sneezing'
p693
aS'2 nasal'
p694
aS'sneezing 34'
p695
aS'12'
p696
aS'8 palate'
p697
aS'8 headache'
p698
aS'34'
p699
aS'1 rhinorrhea'
p700
aS'rhinorrhea 12'
p701
aS'included'
p702
aS'malaise'
p703
aS'remaining'
p704
aS'any local'
p705
aS'rates'
p706
aS'24h'
p707
aS'sample'
p708
aS'administered HBsAg'
p709
aS'activity'
p710
aS'human'
p711
aS'epistaxis'
p712
aS'were more'
p713
aS'HBV vaccine'
p714
aS'following'
p715
aS'sterile'
p716
aS'B virus'
p717
aS'randomized'
p718
aS'sera were'
p719
aS'recipients'
p720
aS'solution'
p721
aS'years'
p722
aS'were recorded'
p723
aS'maximum'
p724
aS'highly'
p725
aS'exploring'
p726
aS'Good'
p727
aS'aimed'
p728
aS'serologic'
p729
aS'receive'
p730
aS'collection sheets'
p731
aS'sheets'
p732
aS'between'
p733
aS'posterior'
p734
aS'cytotoxic'
p735
aS'fifth'
p736
aS'HBsAg following'
p737
aS'linked'
p738
aS'immunized'
p739
aS'HBsAg vaccine'
p740
aS'volunteers immunized'
p741
aS'Drug'
p742
aS'length'
p743
aS'size'
p744
aS'otorhinolaryngologist'
p745
aS'Finlay'
p746
aS'Finlay Hospital'
p747
aS'J Finlay'
p748
aS'Hospital'
p749
aS'confirmed'
p750
aS'adjuvant'
p751
aS'improved'
p752
aS'value'
p753
aS'novel'
p754
aS'drug'
p755
aS'responders anti'
p756
aS'per study'
p757
aS'number'
p758
aS'doses per'
p759
aS'concentration'
p760
aS'treatment group'
p761
aS'Fisher'
p762
aS'enhancement'
p763
aS'written'
p764
aS'based'
p765
aS'severity'
p766
aS'elicit'
p767
aS'work'
p768
aS'history'
p769
aS'potent'
p770
aS'showed'
p771
aS'Nasal administration'
p772
aS'chronic carriers'
p773
aS'HBc seroconversion'
p774
aS'intranasal'
p775
aS'address'
p776
aS'77'
p777
aS'Th cell'
p778
aS'nucleic acids'
p779
aS'previously'
p780
aS'enzyme linked'
p781
aS'expressed'
p782
aS'up'
p783
aS'CIGB'
p784
aS'study staff'
p785
aS'licensed nasal'
p786
aS'give'
p787
aS'formal'
p788
aS'fluorescent'
p789
aS'50g'
p790
aS'M cells'
p791
aS'against HBsAg'
p792
aS'fever'
p793
aS'under'
p794
aS'inflammatory'
p795
aS'significant'
p796
aS'resolving'
p797
aS'effects'
p798
aS'moderate'
p799
aS'received'
p800
aS'there'
p801
aS'over'
p802
aS'differences'
p803
aS'only'
p804
aS'were evaluated'
p805
aS'antibodies'
p806
aS'mucosa'
p807
aS'reporting'
p808
aS'significantly'
p809
aS'Anti HBs'
p810
aS'made'
p811
aS'damage'
p812
aS'ELISA'
p813
aS'ELISA kits'
p814
aS'kits'
p815
aS'observation'
p816
aS'assigned'
p817
aS'Furthermore'
p818
aS'HBV infected'
p819
aS'mean'
p820
aS'assessed'
p821
aS'within'
p822
aS'l per'
p823
aS'hyper'
p824
aS'higher'
p825
aS'serum antibody'
p826
aS'vaccine doses'
p827
aS'71'
p828
aS'mixed'
p829
aS'testing'
p830
aS'Nasal'
p831
aS'Health'
p832
aS'Organization'
p833
aS'Health Organization'
p834
aS'prior'
p835
aS'25'
p836
aS'12h 24h'
p837
aS'24h 48h'
p838
aS'48h 72h'
p839
aS'48h'
p840
aS'actively'
p841
aS'were actively'
p842
aS'actively recorded'
p843
aS'via nasal'
p844
aS'via'
p845
aS'after each'
p846
aS'vaccine dose'
p847
aS'wash'
p848
aS'pre'
p849
aS'defined'
p850
aS'conditions'
p851
aS'level'
p852
aS'NASVAC'
p853
aS'allocated'
p854
aS'saline solution'
p855
aS'saline'
p856
aS'volume'
p857
aS'5ml'
p858
aS'B vaccine'
p859
aS'per nostril'
p860
aS'nostril'
p861
aS'available'
p862
aS'showing'
p863
aS'controlled'
p864
aS'placebo controlled'
p865
aS'male'
p866
aS'healthy male'
p867
aS'methods'
p868
aS'randomly allocated'
p869
aS'randomly'
p870
aS'were also'
p871
aS'similar'
p872
aS'induction'
p873
aS'All subjects'
p874
aS'such'
p875
aS'provided'
p876
aS'component'
p877
aS'frequent'
p878
aS'cases'
p879
aS'measured'
p880
aS'medical'
p881
aS'than 10IU'
p882
aS'DC'
p883
aS'male adults'
p884
aS'test'
p885
aS'Individuals'
p886
aS'clearly'
p887
aS'containing'
p888
aS'Briefly'
p889
aS'thank'
p890
aS'seroprotected'
p891
aS'incubated'
p892
aS'physiologic'
p893
aS'physiologic saline'
p894
aS'comparison'
p895
aS'consent'
p896
aS'informed consent'
p897
aS'informed'
p898
aS'particle'
p899
aS'Recent'
p900
aS'tests'
p901
aS'proportional'
p902
aS'conjugate'
p903
aS'HBc antibodies'
p904
aS'purity'
p905
aS'estimated'
p906
aS'Similarly'
p907
aS'cells'
p908
aS'rats'
p909
aS'Th'
p910
aS'interaction'
p911
aS'nucleic'
p912
aS'neither'
p913
aS'enzyme'
p914
aS'Blood'
p915
aS'CIGB Havana'
p916
aS'particulate'
p917
aS'permanent'
p918
aS'bothersome'
p919
aS'subject'
p920
aS'Recombinant'
p921
aS'levels'
p922
aS'HB'
p923
aS'Heberbiovac HB'
p924
aS'Heberbiovac'
p925
aS'co administration'
p926
aS'hour'
p927
aS'hour after'
p928
aS'between vaccine'
p929
aS'period'
p930
aS'rate'
p931
aS'HBs antibody'
p932
aS'antibody levels'
p933
aS'subtype'
p934
aS'HBsAg subtype'
p935
aS'comprising'
p936
aS'Local'
p937
aS'against HBcAg'
p938
aS'Local site'
p939
aS'site'
p940
aS'through'
p941
aS'100IU'
p942
aS'acute'
p943
aS'Only'
p944
aS'intervals'
p945
aS'There'
p946
aS'There were'
p947
aS'virus HBV'
p948
aS'individuals'
p949
aS'withdrew'
p950
aS'nor'
p951
aS'responder'
p952
aS'adverse reactions'
p953
aS'symptom'
p954
aS'were defined'
p955
aS'nasal flu'
p956
aS'flu'
p957
aS'HBs titers'
p958
aS'were reported'
p959
aS'gene'
p960
aS'temperature'
p961
aS'cell'
p962
aS'following inoculation'
p963
aS'derived'
p964
aS'group withdrew'
p965
aS'inoculated'
p966
aS'needed'
p967
aS'reaction'
p968
aS'comprising HBV'
p969
aS'candidate comprising'
p970
aS'demonstration'
p971
aS'nostril Adverse'
p972
aS'75 All'
p973
aS'Adverse reactions'
p974
aS'titer 10IU'
p975
aS'titers were'
p976
aS'dose Anti'
p977
aS'recorded 1h'
p978
aS'seronegative during'
p979
aS'were all'
p980
aS'remained seronegative'
p981
aS'1h 6h'
p982
aS'evaluated using'
p983
aS'1h'
p984
aS'using corresponding'
p985
aS'HBc titers'
p986
aS'corresponding ELISA'
p987
aS'schedule while'
p988
aS'while'
p989
aS'elicited anti'
p990
aS'tolerated Adverse'
p991
aS'all self'
p992
aS'HBs titer'
p993
aS'reactions included'
p994
aS'dosages'
p995
aS'9 physiologic'
p996
aS'surface HBsAg'
p997
aS'guidelines'
p998
aS'comprising hepatitis'
p999
aS'blinded placebo'
p1000
aS'recombinant antigens'
p1001
aS'Practice guidelines'
p1002
aS'antigens HBcAg'
p1003
aS'controlled randomized'
p1004
aS'randomized clinical'
p1005
aS'models'
p1006
aS'Participants ranged'
p1007
aS'Clinical'
p1008
aS'candidate NASVAC'
p1009
aS'ranged'
p1010
aS'Practice'
p1011
aS'Clinical Practice'
p1012
aS'guidelines Participants'
p1013
aS'markers'
p1014
aS'HBV recombinant'
p1015
aS'HBV surface'
p1016
aS'NASVAC comprising'
p1017
aS'nature'
p1018
aS'II'
p1019
aS'protective'
p1020
aS'wash samples'
p1021
aS'protective levels'
p1022
aS'dripping'
p1023
aS'anterior'
p1024
aS'samples were'
p1025
aS'adjuvants'
p1026
aS'Becton'
p1027
aS'Accuspray Becton'
p1028
aS'Dickinson'
p1029
aS'Accuspray'
p1030
aS'Becton Dickinson'
p1031
aS'predominated'
p1032
aS'conducted'
p1033
aS'effect'
p1034
aS'length HBcAg'
p1035
aS'parenteral'
p1036
aS'APCs'
p1037
aS'collected'
p1038
aS'UMELISA'
p1039
aS'reported during'
p1040
aS'assay'
p1041
aS'nasally'
p1042
aS'were given'
p1043
aS'given'
p1044
aS'HBc UMELISA'
p1045
aS'products'
p1046
aS's exact'
p1047
aS'exact'
p1048
aS'exact test'
p1049
aS'immune response'
p1050
aS'determinants'
p1051
aS'nurse'
p1052
aS'substrate'
p1053
aS'phosphatase'
p1054
aS'alkaline'
p1055
aS'alkaline phosphatase'
p1056
aS'symptoms'
p1057
aS'doses were'
p1058
aS'mean anti'
p1059
aS'irritating'
p1060
aS'known'
p1061
aS'confidence'
p1062
aS'confidence intervals'
p1063
aS'intervals were'
p1064
aS'Individuals were'
p1065
aS'acids'
p1066
aS'events included'
p1067
aS'Solicited'
p1068
aS'immunosorbent'
p1069
aS'linked immunosorbent'
p1070
aS'immunosorbent assay'
p1071
aS'symptom graded'
p1072
aS'graded'
p1073
aS'interference'
p1074
aS'frequently'
p1075
aS'more frequently'
p1076
aS'medical attention'
p1077
aS'require medical'
p1078
aS'may'
p1079
aS'require'
p1080
aS'attention'
p1081
aS'may require'
p1082
aS'reaction category'
p1083
aS'category'
p1084
aS'state'
p1085
aS'sample size'
p1086
aS'dosages of 125l'
p1087
aS'Th1 response vital'
p1088
aS'cost'
p1089
aS'vital'
p1090
aS'protein in suppressing'
p1091
aS'125l per'
p1092
aS'response vital'
p1093
aS'suppressing'
p1094
aS'125l'
p1095
aS'development of more'
p1096
aS'limited'
p1097
aS'candidate for nasal'
p1098
aS'Solicited systemic adverse'
p1099
aS'HBcAg over nasally'
p1100
aS'seroprotection rate'
p1101
aS'facilities'
p1102
aS'randomized placebo'
p1103
aS'hematology tests'
p1104
aS'annoying may require'
p1105
aS'appetite'
p1106
aS'appetite nausea vomiting'
p1107
aS'years There'
p1108
aS'five vaccine'
p1109
aS'group Sneezing'
p1110
aS'spray calcitonin'
p1111
aS'disability'
p1112
aS'height between'
p1113
aS'two participants'
p1114
aS'usual activity'
p1115
aS'Additionally'
p1116
aS'recording of local'
p1117
aS'within 72hours'
p1118
aS'collected at baseline'
p1119
aS'risk'
p1120
aS'physician'
p1121
aS'terminal'
p1122
aS'dripping nasal stuffiness'
p1123
aS'induce strong HBV'
p1124
aS'measured in saliva'
p1125
aS'ulceration and nasal'
p1126
aS'viral'
p1127
aS'immunization interval'
p1128
aS'antibody titer'
p1129
aS'frequent adverse'
p1130
aS'spray at days'
p1131
aS'high mucosal'
p1132
aS'observations at 6h'
p1133
aS'trial corresponding'
p1134
aS'estimates'
p1135
aS'children became'
p1136
aS'Quality Control CECMED'
p1137
aS'subjects having'
p1138
aS'study indicate'
p1139
aS'even'
p1140
aS'post inoculation'
p1141
aS'More than 97'
p1142
aS'HBcAg to act'
p1143
aS'abnormal baseline biochemistry'
p1144
aS'two moderate adverse'
p1145
aS'study screening'
p1146
aS'18 45 years'
p1147
aS'healthy young adults'
p1148
aS'chemical and basic'
p1149
aS'IgA'
p1150
aS'included fever'
p1151
aS'center randomized'
p1152
aS'antibodies were'
p1153
aS'behavioural changes'
p1154
aS'use Nasal'
p1155
aS'frequency of sneezing'
p1156
aS'more immunogenic'
p1157
aS'approximately 5 10'
p1158
aS'analysis Further'
p1159
aS'cutaneous rash Information'
p1160
aS'protection'
p1161
aS'enough to elicit'
p1162
aS'active'
p1163
aS'human sera Briefly'
p1164
aS'behavioral risk'
p1165
aS'formulation consisting'
p1166
aS'irritating potential acute'
p1167
aS'reports'
p1168
aS'Hospital Havana Cuba'
p1169
aS'taking into consideration'
p1170
aS'were kept under'
p1171
aS'Sera with undetectable'
p1172
aS'Recombinant HBsAg reacts'
p1173
aS'changes'
p1174
aS'antibody levels were'
p1175
aS'antibody were'
p1176
aS'explained'
p1177
aS'recipients at day'
p1178
aS'levels and 95'
p1179
aS'significantly higher'
p1180
aS'study vaccines'
p1181
aS'CTL'
p1182
aS'Individuals were excluded'
p1183
aS'moderate or severe'
p1184
aS'other nasal vaccines'
p1185
aS'specific helper'
p1186
aS'nasal itching palate'
p1187
aS'hospital'
p1188
aS'used in specific'
p1189
aS'sampling including antigen'
p1190
aS'tabulated'
p1191
aS'formulation Sterile physiologic'
p1192
aS'nasally administered drugs'
p1193
aS'125 l per'
p1194
aS'therefore'
p1195
aS'Preclinical studies'
p1196
aS'against HBV nucleocapsid'
p1197
aS'aware'
p1198
aS'98'
p1199
aS'muscle aches decreased'
p1200
aS'populations DC'
p1201
aS'Blood saliva'
p1202
aS'most commonly reported'
p1203
aS'administration also allows'
p1204
aS'97'
p1205
aS'All sera'
p1206
aS'HBeAg'
p1207
aS'race predominated'
p1208
aS'adverse event profile'
p1209
aS'anti HBV vaccine'
p1210
aS'mm'
p1211
aS'corresponding to headache'
p1212
aS'phase monoclonal'
p1213
aS'levels were expressed'
p1214
aS'seroconversion against HBcAg'
p1215
aS'6h and 12h'
p1216
aS'All aspects'
p1217
aS'9 Only'
p1218
aS'HBs titers around'
p1219
aS'indicated'
p1220
aS'HBc specific Th'
p1221
aS'were assigned'
p1222
aS'period following'
p1223
aS'persistently abnormal'
p1224
aS'commercial ultramicroanalytic'
p1225
aS'blood mononuclear cells'
p1226
aS'were classified'
p1227
aS'diseases immunosuppressive disorders'
p1228
aS'immunization Solicited'
p1229
aS'subtype CIGB Havana'
p1230
aS'competitive sequential immunoenzymatic'
p1231
aS'vital for viral'
p1232
aS'HBs anti HBc'
p1233
aS'acemannan'
p1234
aS'severe adverse'
p1235
aS'wash samples All'
p1236
aS'HBs antibody level'
p1237
aS'were monitored'
p1238
aS'block antigenic'
p1239
aS'high responders'
p1240
aS'22nm particle'
p1241
aS'dose of 50'
p1242
aS'polymerase'
p1243
aS'43 subjects signed'
p1244
aS'events were monitored'
p1245
aS'multiple comparisons Geometric'
p1246
aS'only 30 days'
p1247
aS'methods Concurrent comparison'
p1248
aS'Genbank accession number'
p1249
aS'device Accuspray'
p1250
aS'percentage anti'
p1251
aS'group with approximately'
p1252
aS'found in participants'
p1253
aS'were seronegative'
p1254
aS'usual activity frequent'
p1255
aS'seroconversion for anti'
p1256
aS'UMELISA Immunoassay'
p1257
aS'vaccine doses were'
p1258
aS'both antigens Rates'
p1259
aS'vaccines currently licensed'
p1260
aS'chronically'
p1261
aS'before'
p1262
aS'use Nasal spray'
p1263
aS'sequential'
p1264
aS'T lymphocytes CTL'
p1265
aS'randomized placebo controlled'
p1266
aS'production'
p1267
aS'nasal mucosa septum'
p1268
aS'Health Organization standard'
p1269
aS'400'
p1270
aS'methodologies for mucosal'
p1271
aS'contained 0 6ml'
p1272
aS'overcome'
p1273
aS'lymphocytes CTL level'
p1274
aS'antigenic determinants'
p1275
aS'other symptom'
p1276
aS'diseases'
p1277
aS'minimum ensured'
p1278
aS'immunoenzymatic'
p1279
aS'sequential immunoenzymatic assay'
p1280
aS'break'
p1281
aS'inoculation under'
p1282
aS'first hour'
p1283
aS'plates'
p1284
aS'immunogen'
p1285
aS'commercial anti HBV'
p1286
aS'Control'
p1287
aS'achieve protective'
p1288
aS'entire core'
p1289
aS'reasonably'
p1290
aS'classified'
p1291
aS'77 recorded adverse'
p1292
aS'existing antibody against'
p1293
aS'conjugate anti HBs'
p1294
aS'under routine use'
p1295
aS'thin cytoplasm'
p1296
aS'nasal adverse reactions'
p1297
aS'commercial anti HBs'
p1298
aS'per well coated'
p1299
aS'side'
p1300
aS'clinically apparent'
p1301
aS'periodical examinations'
p1302
aS'vaccine group reported'
p1303
aS'surface M cell'
p1304
aS'toxicology or otorhinolaryngology'
p1305
aS'nostril were given'
p1306
aS'very distressing interference'
p1307
aS'glycosylated'
p1308
aS'bleeding Solicited'
p1309
aS'device Accuspray Becton'
p1310
aS'seroprotective response'
p1311
aS'substantially'
p1312
aS'preliminary'
p1313
aS'higher than 10IU'
p1314
aS'network'
p1315
aS'prophylactic vaccines'
p1316
aS'characteristic'
p1317
aS'reported more'
p1318
aS'high responders anti'
p1319
aS'medicine'
p1320
aS'Toxicology CENATOX'
p1321
aS'vaccine antigens'
p1322
aS'screening at day'
p1323
aS'route showing'
p1324
aS'anti HBs anti'
p1325
aS'Conversely patients resolving'
p1326
aS'site adverse'
p1327
aS'monoclonal antibodies'
p1328
aS'day period following'
p1329
aS'B infection'
p1330
aS'cirrhosis'
p1331
aS'Concurrent comparison'
p1332
aS'participants prior'
p1333
aS'toxicity and local'
p1334
aS'HBc seroconversion after'
p1335
aS'detecting'
p1336
aS'were made'
p1337
aS'Sneezing palate itching'
p1338
aS'chronic diseases immunosuppressive'
p1339
aS'showed seroconversion'
p1340
aS'study after obtaining'
p1341
aS'had clinically'
p1342
aS'hematological parameters'
p1343
aS'inoculation Adverse'
p1344
aS'long term consequences'
p1345
aS'CENATOX and Carlos'
p1346
aS'doses were needed'
p1347
aS'mucosa septum'
p1348
aS'were combined'
p1349
aS'persistently abnormal baseline'
p1350
aS'sensitivity Similarly further'
p1351
aS'resolving spontaneously'
p1352
aS'signs nor behavioural'
p1353
aS'computer generated list'
p1354
aS'HBc antibody'
p1355
aS'observations'
p1356
aS'addition to self'
p1357
aS'HBsAgHBcAg'
p1358
aS'percentage'
p1359
aS'recent'
p1360
aS'Anti HBc antibody'
p1361
aS'percentages were compared'
p1362
aS'72h following'
p1363
aS'potential acute toxicity'
p1364
aS'HBsAg and 50g'
p1365
aS'there were more'
p1366
aS'other investigators'
p1367
aS'abnormalities in blood'
p1368
aS'HBs 10'
p1369
aS'vaccine using'
p1370
aS'likely'
p1371
aS'incubated with natural'
p1372
aS'sampling including'
p1373
aS'were mostly reported'
p1374
aS'plasmid'
p1375
aS'antigen presenting cells'
p1376
aS'intervals were estimated'
p1377
aS'enables'
p1378
aS'inoculation of any'
p1379
aS'modulatory'
p1380
aS'clinical situation'
p1381
aS'fashion'
p1382
aS'group Individuals'
p1383
aS'levels against HBsAg'
p1384
aS'renal dialysis patients'
p1385
aS'clinical chemistries'
p1386
aS'adverse events reported'
p1387
aS'collected and categorized'
p1388
aS'populations DC Additionally'
p1389
aS'time intervals'
p1390
aS'same time'
p1391
aS'72h after inoculation'
p1392
aS'Center Havana'
p1393
aS'Briefly UMELISA plates'
p1394
aS'infection Conversely patients'
p1395
aS'Conversely patients'
p1396
aS'nasal formulation'
p1397
aS'access Furthermore'
p1398
aS'month after'
p1399
aS'consequences of chronic'
p1400
aS'subtype obtained'
p1401
aS'Nasal spray devices'
p1402
aS'continuous'
p1403
aS'estimate each rate'
p1404
aS'immunization schedule Following'
p1405
aS'any other symptom'
p1406
aS'well known nasally'
p1407
aS'mouth'
p1408
aS'Two applications per'
p1409
aS'Nine participants'
p1410
aS'immunogenicity profile Recent'
p1411
aS'remaining determinants'
p1412
aS'experiments in mice'
p1413
aS'young adults'
p1414
aS'nucleocapsid'
p1415
aS'age weight'
p1416
aS'potential therapeutic'
p1417
aS'principle'
p1418
aS'75 seroprotection'
p1419
aS'72hours following inoculation'
p1420
aS'order to optimize'
p1421
aS'came'
p1422
aS'per well'
p1423
aS'Nasal administration also'
p1424
aS'value 0 05'
p1425
aS'chills headache'
p1426
aS'studies in mice'
p1427
aS'activity frequent'
p1428
aS'measurement of serum'
p1429
aS'events between'
p1430
aS'effects underlines'
p1431
aS'existing antibody'
p1432
aS'intranasal vaccine'
p1433
aS'devices Accuspray'
p1434
aS'5ml Participants'
p1435
aS'90 days'
p1436
aS'range 18 45'
p1437
aS'placebo study'
p1438
aS'combined prophylactic vaccines'
p1439
aS'aches decreased'
p1440
aS'Volunteers were'
p1441
aS'Preclinical mouse studies'
p1442
aS'natural HBsAg'
p1443
aS'immune compromised hosts'
p1444
aS'rabbit anti HBc'
p1445
aS'nasal adverse events'
p1446
aS'three doses were'
p1447
aS'15 minutes apart'
p1448
aS'pocket'
p1449
aS'severity mild moderate'
p1450
aS'polymerase and envelope'
p1451
aS'antibodies were measured'
p1452
aS'report'
p1453
aS'50g HBcAg'
p1454
aS'devices still need'
p1455
aS'infrequent'
p1456
aS'were instructed'
p1457
aS'microscopy'
p1458
aS'consisting'
p1459
aS'through novel'
p1460
aS'mouth Two'
p1461
aS'local damage'
p1462
aS'adverse events predominated'
p1463
aS'study products were'
p1464
aS'Nine participants received'
p1465
aS'100 showed seroconversion'
p1466
aS'experiments conducted'
p1467
aS'treatment display'
p1468
aS'peripheral'
p1469
aS'core antigen'
p1470
aS'alterations'
p1471
aS'dendritic cell'
p1472
aS'patients with self'
p1473
aS'result'
p1474
aS'access very specialized'
p1475
aS'total of two'
p1476
aS'virus HBV worldwide'
p1477
aS'blood samples were'
p1478
aS'other particulate'
p1479
aS'immunization interval protocol'
p1480
aS'500DC'
p1481
aS'frequent and annoying'
p1482
aS'applications per nostril'
p1483
aS'weak HBV'
p1484
aS'05'
p1485
aS'IU l according'
p1486
aS'also likely'
p1487
aS'core antigen gene'
p1488
aS'completion'
p1489
aS'protected'
p1490
aS'older individuals'
p1491
aS'tolerance'
p1492
aS'Clinically significant events'
p1493
aS'HBcAg molecule'
p1494
aS'were closely'
p1495
aS'glycosylated form'
p1496
aS'terms'
p1497
aS'g derived'
p1498
aS'visualization'
p1499
aS'weak'
p1500
aS'patients resolving acute'
p1501
aS'combined prophylactic'
p1502
aS'per nostril were'
p1503
aS'combined HBsAg'
p1504
aS'local and systemic'
p1505
aS'sterile conditions'
p1506
aS'cells PBMCs'
p1507
aS'medication prior inoculation'
p1508
aS'decreased appetite'
p1509
aS'adults Local'
p1510
aS'tests against'
p1511
aS'commercial recombinant'
p1512
aS'up to 71'
p1513
aS'were not involved'
p1514
aS'nasal dripping nasal'
p1515
aS'basis but adverse'
p1516
aS'made for multiple'
p1517
aS'any symptom graded'
p1518
aS'activity on co'
p1519
aS'reach 75 seroprotection'
p1520
aS'reagents 10'
p1521
aS'flu or other'
p1522
aS'revealed by EM'
p1523
aS'well tolerated safe'
p1524
aS'virus after treatment'
p1525
aS'10IU l seroprotection'
p1526
aS'height'
p1527
aS'frequently reported among'
p1528
aS'Board'
p1529
aS'Samples'
p1530
aS'international units per'
p1531
aS'inflammatory analgesics'
p1532
aS'specific post'
p1533
aS'vessel status after'
p1534
aS'fluorigenic'
p1535
aS'vaccine formulation Sterile'
p1536
aS'basis'
p1537
aS'three'
p1538
aS'5 10'
p1539
aS'severe adverse event'
p1540
aS'acids bound'
p1541
aS'formulation and devices'
p1542
aS'same typical'
p1543
aS'type of cytokine'
p1544
aS'life'
p1545
aS'hospitalization'
p1546
aS'efficacy'
p1547
aS'drugs'
p1548
aS'participants were seronegative'
p1549
aS'adverse effects'
p1550
aS'nasal drug'
p1551
aS'hepatitis B infection'
p1552
aS'exception'
p1553
aS'acceptable local adverse'
p1554
aS'Recombinant HBsAg'
p1555
aS'seroprotection with respect'
p1556
aS'events predominated over'
p1557
aS'titers against'
p1558
aS'spontaneously'
p1559
aS'cause interference'
p1560
aS'other reactions'
p1561
aS'years of age'
p1562
aS'procedure'
p1563
aS'life threatening'
p1564
aS'HBcAg as vaccine'
p1565
aS'Sterile physiologic'
p1566
aS'e g acemannan'
p1567
aS'Among'
p1568
aS'subjects were classified'
p1569
aS'impact of HBcAg'
p1570
aS'characterize'
p1571
aS'category and all'
p1572
aS'kind of vaccine'
p1573
aS'vaccine candidate were'
p1574
aS'Nasal spray'
p1575
aS'mouse'
p1576
aS'l low responders'
p1577
aS'immunogenicity studies'
p1578
aS'reported more frequently'
p1579
aS'resolving acute hepatitis'
p1580
aS'cellular responses'
p1581
aS'reports came'
p1582
aS'HBs alkaline'
p1583
aS'also no clinically'
p1584
aS'adults between'
p1585
aS'response in mice'
p1586
aS'serum clinical chemistry'
p1587
aS'vaccine candidate showed'
p1588
aS'day 30 one'
p1589
aS'independent'
p1590
aS'Genbank accession'
p1591
aS'double blinded study'
p1592
aS'formal hypothesis'
p1593
aS'possible'
p1594
aS'60 days All'
p1595
aS'nucleocapsid polymerase'
p1596
aS'co administered'
p1597
aS'All study products'
p1598
aS'antibodies in human'
p1599
aS'Solicited adverse'
p1600
aS'compared'
p1601
aS'adults between 18'
p1602
aS'kept'
p1603
aS'scenario'
p1604
aS'l All'
p1605
aS'HBV worldwide'
p1606
aS'aqueous and transparent'
p1607
aS'contact'
p1608
aS'otorhinolaryngologist examination'
p1609
aS'were more than'
p1610
aS'phase monoclonal antibodies'
p1611
aS'efficacy of antiviral'
p1612
aS'diarrhea'
p1613
aS'days and 90'
p1614
aS'biochemistry or hematology'
p1615
aS'inversely'
p1616
aS'0 73'
p1617
aS'protocol'
p1618
aS'active immunotherapy'
p1619
aS'third vaccine'
p1620
aS'Serious'
p1621
aS'l according'
p1622
aS'same time intervals'
p1623
aS'l Although anti'
p1624
aS'HBs antibodies were'
p1625
aS'cell populations'
p1626
aS'Genbank'
p1627
aS'ability of HBcAg'
p1628
aS'10 l based'
p1629
aS'2 6 13'
p1630
aS'previous'
p1631
aS'professional antigen presenting'
p1632
aS'HBs 100IU'
p1633
aS'antigens NASVAC'
p1634
aS'impaired T cell'
p1635
aS'devices still'
p1636
aS'0 9 sterile'
p1637
aS'other licensed'
p1638
aS'transformed'
p1639
aS'access very'
p1640
aS'evidenced'
p1641
aS'any general'
p1642
aS'drug behavioral'
p1643
aS'8 general malaise'
p1644
aS'advances'
p1645
aS'Clinically significant'
p1646
aS'weight and height'
p1647
aS'neither clinical adverse'
p1648
aS'screening reasons'
p1649
aS'Induction of immunity'
p1650
aS'expiration through'
p1651
aS'C terminal'
p1652
aS'considered hyper responders'
p1653
aS'All study'
p1654
aS'borosilicate 2R'
p1655
aS'apart'
p1656
aS'volunteers were'
p1657
aS'59'
p1658
aS'dosages of 125'
p1659
aS'Also'
p1660
aS'were registered'
p1661
aS'comparability'
p1662
aS'informative'
p1663
aS'immunosuppressive'
p1664
aS'rats revealed'
p1665
aS'measured by commercial'
p1666
aS'titers against HBsAg'
p1667
aS'improved in terms'
p1668
aS'nasal administration'
p1669
aS'buffer without any'
p1670
aS'million carriers'
p1671
aS'responses in mice'
p1672
aS'had abnormalities'
p1673
aS'blood vessel status'
p1674
aS'antibodies No volunteers'
p1675
aS'fifth vaccine'
p1676
aS'single otorhinolaryngologist'
p1677
aS'HBsAg subtype obtained'
p1678
aS'were excluded'
p1679
aS'received either'
p1680
aS'2 whereas systemic'
p1681
aS'antigen gene under'
p1682
aS'Solicited systemic'
p1683
aS'HBsAg and antibody'
p1684
aS'comments'
p1685
aS'seroprotection percentage'
p1686
aS'acknowledge Enrique Iglesias'
p1687
aS'participants were randomized'
p1688
aS'reasons for screen'
p1689
aS'nasal vaccines'
p1690
aS'HBV nucleocapsid'
p1691
aS'recorded by study'
p1692
aS'race predominated during'
p1693
aS'responders to licensed'
p1694
aS'vaccines plant'
p1695
aS'seroprotection over'
p1696
aS'Further'
p1697
aS'highest frequency'
p1698
aS'healthy male adult'
p1699
aS's visits'
p1700
aS'study were similar'
p1701
aS'presence of nucleic'
p1702
aS'activator enabling'
p1703
aS'need for development'
p1704
aS'months'
p1705
aS'nasal dripping'
p1706
aS'system Adverse events'
p1707
aS'staff or volunteers'
p1708
aS'reported by other'
p1709
aS'anti HBs antibodies'
p1710
aS'common scenario'
p1711
aS'nine participants'
p1712
aS'All anti'
p1713
aS'administration comprising HBsAg'
p1714
aS'under sterile conditions'
p1715
aS'nor induced local'
p1716
aS'blood samples'
p1717
aS'dialysis patients'
p1718
aS'placebo study staff'
p1719
aS'received study drug'
p1720
aS'P rez'
p1721
aS'nasal HBsAg HBcAg'
p1722
aS'internal medicine'
p1723
aS'following administration'
p1724
aS'also allows'
p1725
aS'seroconversion against'
p1726
aS'drug behavioral risk'
p1727
aS'support'
p1728
aS'W3110'
p1729
aS'HBc specific'
p1730
aS'vaccines administered through'
p1731
aS'predominated during'
p1732
aS'subjects received'
p1733
aS'posterior nasal'
p1734
aS'ultramicroanalytic enzyme'
p1735
aS'HBsAg and 50'
p1736
aS'head'
p1737
aS'antibody levels against'
p1738
aS'form'
p1739
aS'particulate nature'
p1740
aS'developed NASVAC'
p1741
aS'failure'
p1742
aS'0038 All reactions'
p1743
aS'trained physician specializing'
p1744
aS'recorded adverse'
p1745
aS'true'
p1746
aS'intervals were used'
p1747
aS'absent'
p1748
aS'formal sample size'
p1749
aS'axillary temperature 38'
p1750
aS'antigen presenting'
p1751
aS'sterile saline'
p1752
aS'group reported'
p1753
aS'until'
p1754
aS'phosphate'
p1755
aS'required intervention'
p1756
aS'Serious adverse events'
p1757
aS'between vaccine formulation'
p1758
aS'medication'
p1759
aS'Depending'
p1760
aS'presenting cells'
p1761
aS'within 72h after'
p1762
aS'substantially different than'
p1763
aS'Organization there were'
p1764
aS'principle of neutralization'
p1765
aS'vaccine candidate containing'
p1766
aS'total anti'
p1767
aS'limiting resolving'
p1768
aS'HBV vaccine such'
p1769
aS'dual behavior'
p1770
aS'single center'
p1771
aS'cirrhosis liver failure'
p1772
aS'Only two'
p1773
aS'any clinical data'
p1774
aS'comparisons Geometric mean'
p1775
aS'HBc antibodies 17'
p1776
aS'septum and mucosal'
p1777
aS'multiple comparisons'
p1778
aS'adverse signs nor'
p1779
aS'immunogenic hepatitis'
p1780
aS'HBs alkaline phosphatase'
p1781
aS'medication prior'
p1782
aS'profile Recent'
p1783
aS'system Adverse'
p1784
aS'Similarly further'
p1785
aS'10IU l low'
p1786
aS'effect of systemic'
p1787
aS'disappeared within'
p1788
aS'events were more'
p1789
aS'vaccines administered'
p1790
aS'Health Organization there'
p1791
aS'toxicological'
p1792
aS'period following administration'
p1793
aS'inability to contact'
p1794
aS'self reporting'
p1795
aS'damage In addition'
p1796
aS'administration of HBV'
p1797
aS'fact'
p1798
aS'single nasal vaccine'
p1799
aS'basic hematology'
p1800
aS'patients include'
p1801
aS'adult'
p1802
aS'recombinant HBcAg Biokit'
p1803
aS'Anti HBc UMELISA'
p1804
aS'detecting at least'
p1805
aS'activated'
p1806
aS'volunteer received'
p1807
aS'after each immunization'
p1808
aS'cirrhosis liver'
p1809
aS'Information on any'
p1810
aS'HBV chronically infected'
p1811
aS'ELISA adapted'
p1812
aS'disorders'
p1813
aS'mechanisms for antigen'
p1814
aS'institution Five'
p1815
aS'seroprotection rate increased'
p1816
aS'spray calcitonin salmon'
p1817
aS'defined as axillary'
p1818
aS'adjuvants gene'
p1819
aS'Two applications'
p1820
aS'functioning may require'
p1821
aS'response to HBsAg'
p1822
aS'solution Although there'
p1823
aS'small volumes'
p1824
aS'similar surveillance'
p1825
aS'virus treatment'
p1826
aS'NASVAC or placebo'
p1827
aS'event rate exceeded'
p1828
aS'doses 85'
p1829
aS'units per'
p1830
aS'used Genbank'
p1831
aS'mean antibody titer'
p1832
aS'well documented state'
p1833
aS'Volunteers'
p1834
aS'anti HBc UMELISA'
p1835
aS'chronic infection Conversely'
p1836
aS'prophylactic'
p1837
aS'antibody against hepatitis'
p1838
aS'cell activator enabling'
p1839
aS'applications per'
p1840
aS'received study'
p1841
aS'derived recombinant'
p1842
aS'reported previously'
p1843
aS'antibodies from serum'
p1844
aS'single center randomized'
p1845
aS'0 No abnormalities'
p1846
aS'absent mild'
p1847
aS'luminal surface through'
p1848
aS'prevent'
p1849
aS'bleeding Solicited systemic'
p1850
aS'48hours'
p1851
aS'intranasal vaccine candidate'
p1852
aS'T cell responses'
p1853
aS'undertaken to determine'
p1854
aS'tests against HBsAg'
p1855
aS'demonstrated seroconversion'
p1856
aS'qualitative detection'
p1857
aS'solution All'
p1858
aS'rash Information'
p1859
aS'seroprotected subjects'
p1860
aS'phosphate buffer'
p1861
aS'blood products'
p1862
aS'nasal administration comprising'
p1863
aS'adult volunteers Written'
p1864
aS'assistance'
p1865
aS'under sterile'
p1866
aS'HBc quantification'
p1867
aS'variables Adverse events'
p1868
aS'very specialized'
p1869
aS'acute toxicity'
p1870
aS'vaccine Furthermore'
p1871
aS'boost'
p1872
aS'than 400 million'
p1873
aS'filled'
p1874
aS'liter IU'
p1875
aS'were administered'
p1876
aS'statistically'
p1877
aS'any adverse'
p1878
aS'HBcAg combined'
p1879
aS'ulceration'
p1880
aS'vaccine candidate developed'
p1881
aS'Havana Cuba All'
p1882
aS'mononuclear cells'
p1883
aS'Each vial'
p1884
aS'groups'
p1885
aS'HBs UMELISA'
p1886
aS'along'
p1887
aS'disappeared'
p1888
aS'HBsAg Recombinant HBsAg'
p1889
aS'immunization further benefit'
p1890
aS'informed consent Individuals'
p1891
aS'Research Ethics Board'
p1892
aS'novel adjuvants'
p1893
aS'significant events'
p1894
aS'development of mucosal'
p1895
aS'events included fever'
p1896
aS'reagents'
p1897
aS'differences between'
p1898
aS'recipients 0 0038'
p1899
aS'administered drugs'
p1900
aS'permanent impairment'
p1901
aS'B virus anti'
p1902
aS'sneezing nasal'
p1903
aS'were found'
p1904
aS'nor behavioural'
p1905
aS'bulbs'
p1906
aS'vaccine using similar'
p1907
aS'remaining determinants After'
p1908
aS'sterile phosphate'
p1909
aS'vaccines vaccines'
p1910
aS'lymphocytes CTL'
p1911
aS'visit'
p1912
aS'optimize'
p1913
aS'mucosal nasal'
p1914
aS'least one'
p1915
aS'scenario in patients'
p1916
aS'HBV core'
p1917
aS'hospital for 48hours'
p1918
aS'response in up'
p1919
aS'normal functioning'
p1920
aS'purified from strain'
p1921
aS'organized'
p1922
aS'acceptable'
p1923
aS'apparent'
p1924
aS'envelope'
p1925
aS'were undertaken'
p1926
aS'Recent developments'
p1927
aS'Subjects were healthy'
p1928
aS'participants as minimum'
p1929
aS'400 million'
p1930
aS'Binomial distribution point'
p1931
aS'recombinant Heberbiovac'
p1932
aS'list of random'
p1933
aS'hospitalizations were'
p1934
aS'borosilicate'
p1935
aS'were negative'
p1936
aS'polyclonal and multi'
p1937
aS'28nm as characterized'
p1938
aS'actively and always'
p1939
aS'cell pockets'
p1940
aS'labeled'
p1941
aS'obtained from serum'
p1942
aS'assay anti HBs'
p1943
aS'contact after'
p1944
aS'all other'
p1945
aS'septum'
p1946
aS'Each vial contained'
p1947
aS'g acemannan'
p1948
aS'were assigned arbitrarily'
p1949
aS'18 and 45'
p1950
aS'sera Briefly'
p1951
aS'T cell immunity'
p1952
aS'tilted backwards'
p1953
aS'detect differences'
p1954
aS'group withdrew voluntarily'
p1955
aS'allowed'
p1956
aS'72h after'
p1957
aS'Induction'
p1958
aS'containing recombinant'
p1959
aS'cells M cells'
p1960
aS'CECMED in Cuba'
p1961
aS'dialysis'
p1962
aS'remaining 19 participants'
p1963
aS'immunity Nasal administration'
p1964
aS'chemical'
p1965
aS'level in patients'
p1966
aS'criterion'
p1967
aS'stored in borosilicate'
p1968
aS'terms of sensitivity'
p1969
aS'further benefit'
p1970
aS'contribute'
p1971
aS'immunomodulation on HBsAg'
p1972
aS'spray device'
p1973
aS'strong mucosal'
p1974
aS'500DC mm'
p1975
aS'applications'
p1976
aS'graded as moderate'
p1977
aS'work efficiently'
p1978
aS'performed periodical'
p1979
aS'designed'
p1980
aS'reactions were self'
p1981
aS'placebo delivered'
p1982
aS'vaccine Heberbiovac HB'
p1983
aS'natural'
p1984
aS'liquid'
p1985
aS'persistent or permanent'
p1986
aS'tryptophan promoter'
p1987
aS'vaccine candidate tested'
p1988
aS'second vaccine doses'
p1989
aS'standard parenteral HBV'
p1990
aS'form HBcAg'
p1991
aS'were healthy male'
p1992
aS'immunogen even without'
p1993
aS'ultramicroanalytic'
p1994
aS'HBs equal'
p1995
aS'typical'
p1996
aS'site adverse events'
p1997
aS'72h following inoculation'
p1998
aS'expressed and purified'
p1999
aS'number X02763'
p2000
aS'appetite nausea'
p2001
aS'products were'
p2002
aS'400 million carriers'
p2003
aS'statistical'
p2004
aS'one adverse'
p2005
aS'still'
p2006
aS'microscopy EM'
p2007
aS'monitor'
p2008
aS'local tolerance All'
p2009
aS'proportion hypo'
p2010
aS'adverse event rate'
p2011
aS'B virus treatment'
p2012
aS'useful to overcome'
p2013
aS'HBV chronic infection'
p2014
aS'included persistently'
p2015
aS'nasal vaccine Furthermore'
p2016
aS'nose or digestive'
p2017
aS'uptake'
p2018
aS'serum antibody response'
p2019
aS'than 400'
p2020
aS'resulted in recent'
p2021
aS'phase antigen'
p2022
aS'protein expressed'
p2023
aS'titers around'
p2024
aS'obtaining'
p2025
aS'bound'
p2026
aS'congestion sneezing'
p2027
aS'were eligible'
p2028
aS'limited HBV'
p2029
aS'acknowledge Enrique'
p2030
aS'HBcAg particles'
p2031
aS'Dawley rats'
p2032
aS'HBcAg Biokit Barcelona'
p2033
aS'conjugate anti'
p2034
aS'term'
p2035
aS'UMELISA Immunoassay Center'
p2036
aS'immunoglobulin within'
p2037
aS'proteins'
p2038
aS'total of 43'
p2039
aS'vaccine only'
p2040
aS'85'
p2041
aS'control group'
p2042
aS'study screening reasons'
p2043
aS'following inoculation Adverse'
p2044
aS'abnormal'
p2045
aS'achieve protective anti'
p2046
aS'balanced'
p2047
aS'sponsor'
p2048
aS'year'
p2049
aS'recombinant HBsAg'
p2050
aS'anti HBc quantification'
p2051
aS'induced local'
p2052
aS'Solid phase'
p2053
aS'limited HBV infection'
p2054
aS'borosilicate 2R bulbs'
p2055
aS'continuous variables'
p2056
aS'doses were administered'
p2057
aS'sneezing nasal itching'
p2058
aS'responses against HBV'
p2059
aS'contained'
p2060
aS'according to otorhinolaryngologist'
p2061
aS'8IU'
p2062
aS'vaccine candidate administered'
p2063
aS'helpful comments'
p2064
aS'virus anti'
p2065
aS'format using'
p2066
aS'sense although three'
p2067
aS'excluded from enrollment'
p2068
aS'million'
p2069
aS'year 2000 Among'
p2070
aS'possibility'
p2071
aS'block antigenic determinants'
p2072
aS'secreted'
p2073
aS'first vaccine'
p2074
aS'reacting with remaining'
p2075
aS'generating more than'
p2076
aS'Enrique Iglesias'
p2077
aS'against both'
p2078
aS'virus control'
p2079
aS'allowed expiration through'
p2080
aS'Participants allocated'
p2081
aS'still need'
p2082
aS'also thank'
p2083
aS'routes'
p2084
aS'therapeutic use'
p2085
aS'itching palate itching'
p2086
aS'event in both'
p2087
aS'B cells'
p2088
aS'Sprague'
p2089
aS'symptoms very'
p2090
aS'variables'
p2091
aS'antibody were assigned'
p2092
aS'subjects showing'
p2093
aS'HBc alkaline phosphatase'
p2094
aS'defined as events'
p2095
aS'trial phase'
p2096
aS'Rates'
p2097
aS'periodical'
p2098
aS'comprises'
p2099
aS'100 showed'
p2100
aS'5 More than'
p2101
aS'one adverse event'
p2102
aS'transient nasal conditions'
p2103
aS'group included'
p2104
aS'vaccine or placebo'
p2105
aS'nasal itching'
p2106
aS'nasal spray calcitonin'
p2107
aS'impairment or damage'
p2108
aS'indicate'
p2109
aS'candidate containing recombinant'
p2110
aS'recognize any'
p2111
aS'white'
p2112
aS'cell populations DC'
p2113
aS'systemic immunity Nasal'
p2114
aS'Sneezing'
p2115
aS'mostly'
p2116
aS'II clinical studies'
p2117
aS'either NASVAC'
p2118
aS'immunomodulation'
p2119
aS'even without'
p2120
aS'study personnel before'
p2121
aS'alone or mixed'
p2122
aS'HBcAg CIGB'
p2123
aS'control Recombinant'
p2124
aS'clinical adverse signs'
p2125
aS'9 8 general'
p2126
aS'control Recombinant HBcAg'
p2127
aS'seroconversion after immunization'
p2128
aS'any study'
p2129
aS'13'
p2130
aS'effective'
p2131
aS'17'
p2132
aS'expressed as international'
p2133
aS'Five doses'
p2134
aS'institution Five doses'
p2135
aS'medical consultations'
p2136
aS'typical sandwich'
p2137
aS'within 72h'
p2138
aS'outcome'
p2139
aS'other symptom graded'
p2140
aS'addition of HBcAg'
p2141
aS'under observation'
p2142
aS'HBs or anti'
p2143
aS'other mucosal adjuvant'
p2144
aS'pre existing antibody'
p2145
aS'HBsAg reacts'
p2146
aS'rate percentages were'
p2147
aS'peptide vaccine'
p2148
aS'underlines'
p2149
aS'90 of children'
p2150
aS'up to 20'
p2151
aS'sensitivity Similarly'
p2152
aS'immunogen even'
p2153
aS'30 to get'
p2154
aS'instructed'
p2155
aS'19 participants'
p2156
aS'performance'
p2157
aS'impairment'
p2158
aS'l low'
p2159
aS'analysis Further antigenicity'
p2160
aS'HBV infected patients'
p2161
aS'multiple'
p2162
aS'trace'
p2163
aS'specific Th'
p2164
aS'Biotechnology in Havana'
p2165
aS'50g HBsAg'
p2166
aS'gene under'
p2167
aS'molecule'
p2168
aS'0 5ml Participants'
p2169
aS'study 100'
p2170
aS'positive or negative'
p2171
aS'detect'
p2172
aS'significantly increases'
p2173
aS'previous findings'
p2174
aS'Th1 type'
p2175
aS'characteristic of HBV'
p2176
aS'cellular responses against'
p2177
aS'adverse signs'
p2178
aS'participant s head'
p2179
aS'Becton Dickinson Depending'
p2180
aS'determinants After'
p2181
aS'renal'
p2182
aS'without any adjuvant'
p2183
aS'majority of infected'
p2184
aS'professional'
p2185
aS'were expressed'
p2186
aS'estimated by treatment'
p2187
aS'rate percentages'
p2188
aS'substantially different'
p2189
aS'virus as well'
p2190
aS'severity Binomial distribution'
p2191
aS'accession'
p2192
aS'parenteral administered HBsAg'
p2193
aS'tryptophan'
p2194
aS'HBsAg titer'
p2195
aS'events 58'
p2196
aS'ratio'
p2197
aS'All blood'
p2198
aS'male adult volunteers'
p2199
aS'study group included'
p2200
aS'potential acute'
p2201
aS'otorhinolaryngology'
p2202
aS'Concurrent'
p2203
aS'Binomial'
p2204
aS'Severe reactions were'
p2205
aS'HBs protective levels'
p2206
aS'previously for other'
p2207
aS'showed protective levels'
p2208
aS'More than'
p2209
aS'get'
p2210
aS'history of hepatitis'
p2211
aS'reported among'
p2212
aS'mixed with other'
p2213
aS'candidate demonstrated'
p2214
aS'ultramicroanalytic enzyme linked'
p2215
aS'S protein expressed'
p2216
aS'13 excess'
p2217
aS'secondary'
p2218
aS'same typical sandwich'
p2219
aS'regarding'
p2220
aS'vaccine Furthermore participants'
p2221
aS'age of participants'
p2222
aS'axillary temperature 39'
p2223
aS'symptom bothersome'
p2224
aS'physicians or volunteers'
p2225
aS'infection resolving'
p2226
aS'M cells transport'
p2227
aS'were used'
p2228
aS'true adverse event'
p2229
aS'audited'
p2230
aS'frequency of local'
p2231
aS'HBV core HBc'
p2232
aS'HBV nucleocapsid polymerase'
p2233
aS'adapted to small'
p2234
aS'sterile aqueous'
p2235
aS'cell immune response'
p2236
aS'per liter IU'
p2237
aS'2IU'
p2238
aS'licensed HBV'
p2239
aS'Hospital Havana'
p2240
aS'Organization standard'
p2241
aS'itching rhinorrhea nasal'
p2242
aS'investigators with licensed'
p2243
aS'study one subject'
p2244
aS'one month'
p2245
aS'blood screening regarding'
p2246
aS'candidate were'
p2247
aS'seronegative for anti'
p2248
aS'diarrhea and cutaneous'
p2249
aS'total of 77'
p2250
aS'mostly reported'
p2251
aS'1 hour'
p2252
aS'subjects were considered'
p2253
aS'similar surveillance methods'
p2254
aS'therapies'
p2255
aS'schedule Following administration'
p2256
aS'moderate adverse events'
p2257
aS'healthy adults Local'
p2258
aS'fluorescent signal'
p2259
aS'B vaccine candidate'
p2260
aS'personnel before'
p2261
aS'screen'
p2262
aS'g acemannan Whether'
p2263
aS'induced serum antibody'
p2264
aS'gratefully'
p2265
aS'chemistries and hematology'
p2266
aS'steroid'
p2267
aS'Each'
p2268
aS'also contribute'
p2269
aS'both reports came'
p2270
aS'HBsAg Recombinant'
p2271
aS'vaccine and one'
p2272
aS'purified recombinant'
p2273
aS'very specialized mechanisms'
p2274
aS'Sterile'
p2275
aS'vaccine were given'
p2276
aS'analgesics'
p2277
aS'residence'
p2278
aS'events did'
p2279
aS'more frequently reported'
p2280
aS'enabling'
p2281
aS'Chronic'
p2282
aS'participants were instructed'
p2283
aS'predominated over'
p2284
aS'induce strong'
p2285
aS'nor behavioural changes'
p2286
aS'vaccine recipients achieved'
p2287
aS'further studies'
p2288
aS'preclinical studies'
p2289
aS'Iglesias'
p2290
aS'immunity in chronic'
p2291
aS'were compared'
p2292
aS'77 adverse'
p2293
aS'studies were conducted'
p2294
aS'stored'
p2295
aS'them were'
p2296
aS'Recent advances'
p2297
aS'sampling'
p2298
aS'itching rhinorrhea'
p2299
aS'undetectable anti'
p2300
aS'most frequent adverse'
p2301
aS'considering'
p2302
aS'anosmia'
p2303
aS'achieved by nasal'
p2304
aS'Research'
p2305
aS'purified with recombinant'
p2306
aS'tonsils'
p2307
aS'registered Only'
p2308
aS'HBsAg and 100'
p2309
aS'antiviral immunogenicity'
p2310
aS'stuffiness and epistaxis'
p2311
aS'Clinically'
p2312
aS'immunopotentiating activity'
p2313
aS'sponsor institution'
p2314
aS'Subjects were'
p2315
aS'over systemic reactions'
p2316
aS'anti HBs 10'
p2317
aS'parenteral HBV'
p2318
aS'careful'
p2319
aS'73 provided'
p2320
aS'apparent abnormalities visualized'
p2321
aS'Biokit Barcelona Spain'
p2322
aS'plant derived vaccines'
p2323
aS'nasal flu vaccine'
p2324
aS'distressing'
p2325
aS'efficiently'
p2326
aS'T lymphocytes'
p2327
aS'buffer without'
p2328
aS'Spain'
p2329
aS'regarding chemical'
p2330
aS'vaccine doses Local'
p2331
aS'frequently in participants'
p2332
aS'region'
p2333
aS'clinically apparent abnormalities'
p2334
aS'used to estimate'
p2335
aS'HBc alkaline'
p2336
aS'within 72hours following'
p2337
aS'Iglesias P rez'
p2338
aS'compared by Fisher'
p2339
aS'them'
p2340
aS'equal'
p2341
aS'strain'
p2342
aS'good'
p2343
aS'inversely proportional'
p2344
aS'patients and carriers'
p2345
aS'were stored'
p2346
aS'long term'
p2347
aS'alterations or transient'
p2348
aS'diluted in sterile'
p2349
aS'helpful comments Finally'
p2350
aS'congestion sneezing nasal'
p2351
aS'encouraging taking'
p2352
aS'different'
p2353
aS'participant'
p2354
aS'through novel routes'
p2355
aS'spray device Accuspray'
p2356
aS'doctor'
p2357
aS'formulations'
p2358
aS'All but two'
p2359
aS'electron microscopy EM'
p2360
aS'surveillance'
p2361
aS'induction of immunity'
p2362
aS'further immunogenicity studies'
p2363
aS'full length recombinant'
p2364
aS'status'
p2365
aS'internal medicine toxicology'
p2366
aS'commonly reported'
p2367
aS'levels were'
p2368
aS'particulate antigens'
p2369
aS'0 0038 All'
p2370
aS'IU'
p2371
aS'formulation Phase II'
p2372
aS'Barcelona'
p2373
aS'route showing induction'
p2374
aS'sample size nine'
p2375
aS'l in order'
p2376
aS'seroprotected subjects were'
p2377
aS'total serum antibody'
p2378
aS'self limiting resolving'
p2379
aS'evaluated in duplicate'
p2380
aS'very encouraging'
p2381
aS'eligible'
p2382
aS'defined as absent'
p2383
aS'chronic patients include'
p2384
aS'became chronic carriers'
p2385
aS'steroid anti inflammatory'
p2386
aS'baseline 30'
p2387
aS'studies with HBsAg'
p2388
aS'other commercial'
p2389
aS'were more frequently'
p2390
aS'findings in experiments'
p2391
aS'cell immunity'
p2392
aS'inability'
p2393
aS'placebo group 59'
p2394
aS'g nasal flu'
p2395
aS'persistently'
p2396
aS'reporting adverse events'
p2397
aS'sprayed'
p2398
aS'Only anti HBs'
p2399
aS'levels against'
p2400
aS'among'
p2401
aS'adjustments'
p2402
aS'local or systemic'
p2403
aS'cytotoxic T cell'
p2404
aS'showed protective'
p2405
aS'Solicited adverse events'
p2406
aS'all participants were'
p2407
aS'behavioural'
p2408
aS'72hours following'
p2409
aS'comparisons Geometric'
p2410
aS'infrequent Adverse events'
p2411
aS'rats revealed neither'
p2412
aS'strong mucosal immunogenicity'
p2413
aS'patients include combined'
p2414
aS'placebo All study'
p2415
aS'immunogenicity of nasal'
p2416
aS'such samples'
p2417
aS'90 day period'
p2418
aS'Ethics'
p2419
aS'antigenicity studies'
p2420
aS'aspects'
p2421
aS'around'
p2422
aS'blinded fashion'
p2423
aS'mucosal alterations'
p2424
aS'were monitored over'
p2425
aS'recipient'
p2426
aS'90 applied doses'
p2427
aS'infected patient'
p2428
aS'were estimated pre'
p2429
aS'aqueous'
p2430
aS'irritating nor induced'
p2431
aS'corroborates previous'
p2432
aS'failures included'
p2433
aS'45 years There'
p2434
aS'envelope proteins'
p2435
aS'benefit'
p2436
aS'Subjects'
p2437
aS'either'
p2438
aS'hematology values'
p2439
aS'side effects'
p2440
aS'reported by 15'
p2441
aS'64'
p2442
aS'voluntarily'
p2443
aS'partial efficacy'
p2444
aS'recognize'
p2445
aS'candidate whereas systemic'
p2446
aS'50 g derived'
p2447
aS'than 97'
p2448
aS'than 95'
p2449
aS'influenza nasal flu'
p2450
aS'assay ELISA adapted'
p2451
aS'immunization with HBsAg'
p2452
aS'ability'
p2453
aS'HBcAg considering'
p2454
aS'HBsAg alone'
p2455
aS'doses Local'
p2456
aS'response to major'
p2457
aS'dependent and independent'
p2458
aS'specializing'
p2459
aS'allocation All'
p2460
aS'palate itching anosmia'
p2461
aS'cytotoxic T lymphocytes'
p2462
aS'chronic HBV infection'
p2463
aS'visits'
p2464
aS'7 years range'
p2465
aS'solid phase monoclonal'
p2466
aS'50 g purified'
p2467
aS'PBMCs from patients'
p2468
aS'nasal vaccine formulation'
p2469
aS'fifth dose'
p2470
aS'25 showed'
p2471
aS'categorized by body'
p2472
aS'cost and side'
p2473
aS'post immunization sera'
p2474
aS'apart All subjects'
p2475
aS'mice reconstituted'
p2476
aS'pockets'
p2477
aS'act'
p2478
aS'local tolerance'
p2479
aS'code labeled'
p2480
aS'Information'
p2481
aS'other mucosal'
p2482
aS'prolonged hospitalization'
p2483
aS'study and control'
p2484
aS'without any'
p2485
aS'major HBV'
p2486
aS'terminal region'
p2487
aS'trial were'
p2488
aS'HBsAg 10IU'
p2489
aS'immunogenicity Preclinical'
p2490
aS'determine'
p2491
aS'immunization further'
p2492
aS'intervention'
p2493
aS'proportion hypo responders'
p2494
aS'conflict of interest'
p2495
aS'g derived recombinant'
p2496
aS'g influenza nasal'
p2497
aS'than 95 purity'
p2498
aS'underwent pre study'
p2499
aS'enhancement observed'
p2500
aS'low'
p2501
aS'days All sera'
p2502
aS'secretion'
p2503
aS'needed to reach'
p2504
aS'30 Thirty'
p2505
aS'were self limiting'
p2506
aS'also allows interaction'
p2507
aS'professional antigen'
p2508
aS'Individuals were eligible'
p2509
aS'hyper responders'
p2510
aS'l One recipient'
p2511
aS'HBs anti'
p2512
aS'human clinical'
p2513
aS'physician specializing'
p2514
aS'antigenicity studies were'
p2515
aS'first report'
p2516
aS'combined formulations'
p2517
aS'Sprague Dawley'
p2518
aS'antigen gene'
p2519
aS'temperature 38'
p2520
aS'labeled matched pre'
p2521
aS'surface and core'
p2522
aS'side effects underlines'
p2523
aS'were conducted'
p2524
aS'dose however five'
p2525
aS'dose schedule formulation'
p2526
aS'inoculation Blood'
p2527
aS'wash samples were'
p2528
aS'interval'
p2529
aS'USA'
p2530
aS'l Sera'
p2531
aS'measurement'
p2532
aS'reporting adverse'
p2533
aS'blood mononuclear'
p2534
aS'enable'
p2535
aS'Th1 response'
p2536
aS'point estimates'
p2537
aS'size of 28nm'
p2538
aS'nasally administered'
p2539
aS'recombinant full'
p2540
aS'biochemistry'
p2541
aS'2000'
p2542
aS'underwent pre'
p2543
aS'efficiently as primary'
p2544
aS'comments Finally'
p2545
aS'pre incubated'
p2546
aS'More'
p2547
aS'presenting'
p2548
aS'requested'
p2549
aS'antibody titers'
p2550
aS'Preclinical toxicological studies'
p2551
aS'otorhinolaryngology Neither'
p2552
aS'more than 95'
p2553
aS'potent immunogen'
p2554
aS'post inoculation adverse'
p2555
aS'specializing in internal'
p2556
aS'each nostril'
p2557
aS'vaccine candidate demonstrated'
p2558
aS'irritating nor'
p2559
aS'any general reaction'
p2560
aS'documented state'
p2561
aS'liquid Each'
p2562
aS'event profile under'
p2563
aS'Briefly UMELISA'
p2564
aS'mixed with 50'
p2565
aS'were recruited'
p2566
aS'immunoglobulin'
p2567
aS'placebo All'
p2568
aS'behavioral'
p2569
aS'other developed'
p2570
aS'per liter'
p2571
aS'influenza'
p2572
aS'estimated pre'
p2573
aS'consider'
p2574
aS'more immunogenic hepatitis'
p2575
aS'caused'
p2576
aS'withdrew voluntarily'
p2577
aS'month'
p2578
aS'vaccines currently'
p2579
aS'25 showed protective'
p2580
aS'first and second'
p2581
aS'basic hematological'
p2582
aS'HBsAgHBcAg vaccine'
p2583
aS'tabulated by time'
p2584
aS'related to any'
p2585
aS'children'
p2586
aS'2R bulbs'
p2587
aS'monitored over'
p2588
aS'two seroprotected'
p2589
aS'frequent adverse events'
p2590
aS'entire core antigen'
p2591
aS'events predominated'
p2592
aS'novel adjuvants gene'
p2593
aS'cells APCs'
p2594
aS'HBcAg had'
p2595
aS'risk factors'
p2596
aS'M cell'
p2597
aS'liter'
p2598
aS'geometric mean anti'
p2599
aS'1 to vaccine'
p2600
aS'induce'
p2601
aS'All reactions'
p2602
aS'get 25'
p2603
aS'device Also'
p2604
aS'HBcAg nasal'
p2605
aS'viral clearance'
p2606
aS'difference'
p2607
aS'similar proportion'
p2608
aS'head tilted'
p2609
aS'any adverse event'
p2610
aS'children became chronic'
p2611
aS'90 days following'
p2612
aS'list'
p2613
aS'prolonged'
p2614
aS'recipients one month'
p2615
aS'were registered Only'
p2616
aS'HBsAg used'
p2617
aS'small'
p2618
aS'infection resolving spontaneously'
p2619
aS'vaccines vaccines administered'
p2620
aS'surveillance methods Concurrent'
p2621
aS'revealed neither'
p2622
aS'antibodies and 25'
p2623
aS'seroprotective antibody titers'
p2624
aS'medical monitor'
p2625
aS'Similarly further assays'
p2626
aS'within 6 months'
p2627
aS'parenteral administered'
p2628
aS'Havana Cuba licensed'
p2629
aS'good safety'
p2630
aS'functioning'
p2631
aS'very distressing'
p2632
aS'enough to cause'
p2633
aS'immunization sera Only'
p2634
aS'10 l per'
p2635
aS'hour after each'
p2636
aS'reconstituted with peripheral'
p2637
aS'Engineering Biotechnology Havana'
p2638
aS'presence'
p2639
aS'samples All'
p2640
aS'behavioral risk factors'
p2641
aS'vomiting'
p2642
aS'events reported'
p2643
aS'animals under'
p2644
aS'HB CIGB'
p2645
aS'excess'
p2646
aS'planned medical consultations'
p2647
aS'nasal drug behavioral'
p2648
aS'significant acute'
p2649
aS'rate exceeded 15'
p2650
aS'immunity against HBV'
p2651
aS'Phase II'
p2652
aS'concluded at day'
p2653
aS'allows'
p2654
aS'after treatment'
p2655
aS'levels of anti'
p2656
aS'vaccine studies'
p2657
aS'novel routes'
p2658
aS'period and severity'
p2659
aS'antibody responses against'
p2660
aS'0 6ml'
p2661
aS'g Miacalcin nasal'
p2662
aS'dose injection'
p2663
aS'chronically infected'
p2664
aS'involved in collection'
p2665
aS'toxicity'
p2666
aS'All subjects received'
p2667
aS'patients resolving'
p2668
aS'more than 400'
p2669
aS'were also collected'
p2670
aS'volunteers Written informed'
p2671
aS'placebo group Individuals'
p2672
aS'pockets enable'
p2673
aS'anosmia nasal'
p2674
aS'immunoenhancing'
p2675
aS'surveillance methods'
p2676
aS'events within'
p2677
aS'commercial recombinant HBcAg'
p2678
aS'immunosuppressive disorders'
p2679
aS'trained'
p2680
aS'calcitonin salmon Novartis'
p2681
aS'mononuclear'
p2682
aS'containing recombinant hepatitis'
p2683
aS'alkaline phosphatase conjugate'
p2684
aS'B cell activator'
p2685
aS'clearly demonstrates'
p2686
aS'l for analysis'
p2687
aS'interval protocol'
p2688
aS'CTL level'
p2689
aS'intervention to prevent'
p2690
aS'received either NASVAC'
p2691
aS'geometric mean antibody'
p2692
aS'available for testing'
p2693
aS'were requested'
p2694
aS'outpatient'
p2695
aS'Drug Quality Control'
p2696
aS'tested'
p2697
aS'anti HBs ELISA'
p2698
aS'were mild self'
p2699
aS'cell dependent'
p2700
aS'Cuba licensed hepatitis'
p2701
aS'drug over'
p2702
aS'administration of successive'
p2703
aS'avoid anterior'
p2704
aS'strong HBV core'
p2705
aS'mean antibody'
p2706
aS'placebo controlled double'
p2707
aS'support further phase'
p2708
aS'l and high'
p2709
aS'nine'
p2710
aS'mostly reported during'
p2711
aS'any symptom'
p2712
aS'well coated'
p2713
aS'fever chills headache'
p2714
aS'volunteer received either'
p2715
aS'include combined'
p2716
aS'antigens Rates'
p2717
aS'group sample size'
p2718
aS'observation period concluded'
p2719
aS'All blood samples'
p2720
aS'potential therapeutic use'
p2721
aS'minimum'
p2722
aS'higher than'
p2723
aS'numbers'
p2724
aS'tract'
p2725
aS'sense'
p2726
aS'HBsAg immunogenicity'
p2727
aS'activated B cells'
p2728
aS'developed antibodies'
p2729
aS'inoculation under sterile'
p2730
aS'against both antigens'
p2731
aS'baseline all participants'
p2732
aS'antibodies against HBsAg'
p2733
aS'fluorigenic substrate'
p2734
aS'defined as concentration'
p2735
aS'multi specific'
p2736
aS'hypo responders'
p2737
aS'titer Anti'
p2738
aS'cases of fever'
p2739
aS'l in such'
p2740
aS'activator'
p2741
aS'routine use'
p2742
aS'plant'
p2743
aS'sandwich'
p2744
aS'percentages were'
p2745
aS'mild No development'
p2746
aS's head tilted'
p2747
aS'known nasally administered'
p2748
aS'true adverse'
p2749
aS'otorhinolaryngologist performed periodical'
p2750
aS'two seroprotected vaccine'
p2751
aS'buffer'
p2752
aS'enables antigens'
p2753
aS'Withdrawal'
p2754
aS'There were also'
p2755
aS'l based'
p2756
aS'results indicated'
p2757
aS'recombinant full length'
p2758
aS'ELISA kits Samples'
p2759
aS'rhinorrhea nasal stuffiness'
p2760
aS'superior to 95'
p2761
aS'chemistries'
p2762
aS'chronically infected patients'
p2763
aS'transient nasal'
p2764
aS'failures included persistently'
p2765
aS'safety and preliminary'
p2766
aS'T cell dependent'
p2767
aS'signs nor'
p2768
aS'enabling activated'
p2769
aS'specific post inoculation'
p2770
aS'group included sneezing'
p2771
aS'cell activator'
p2772
aS'between 18'
p2773
aS'made actively'
p2774
aS'signs'
p2775
aS'HBsAgHBcAg vaccine candidate'
p2776
aS'gratefully acknowledge Enrique'
p2777
aS'20'
p2778
aS'5ml Participants allocated'
p2779
aS'luminal surface'
p2780
aS'UMELISA plates 10'
p2781
aS'nasal immunization'
p2782
aS'moderate adverse'
p2783
aS'detected'
p2784
aS'were available'
p2785
aS'Local site adverse'
p2786
aS'volunteer generating more'
p2787
aS'placebo developed'
p2788
aS'antibody response'
p2789
aS'HBsAg mixed'
p2790
aS'drugs of protein'
p2791
aS'2R'
p2792
aS'effective approach'
p2793
aS'baseline 30 days'
p2794
aS'encouraging'
p2795
aS'medicine toxicology'
p2796
aS'unexpected or severe'
p2797
aS'Immunoassay Center'
p2798
aS'cell pockets enable'
p2799
aS'generating more'
p2800
aS'natural HBsAg subtype'
p2801
aS'g influenza'
p2802
aS'HBcAg Biokit'
p2803
aS'seroprotected vaccine recipients'
p2804
aS'became chronic'
p2805
aS'palate itching rhinorrhea'
p2806
aS'determine mucosal'
p2807
aS'antibodies 17'
p2808
aS'always'
p2809
aS'assistance and helpful'
p2810
aS'Further antigenicity studies'
p2811
aS'Only anti'
p2812
aS'did'
p2813
aS'collection of any'
p2814
aS'obtaining written informed'
p2815
aS'found'
p2816
aS'difficult'
p2817
aS'were collected'
p2818
aS'characterized'
p2819
aS'defects'
p2820
aS'excess over'
p2821
aS'Following administration'
p2822
aS'tilted'
p2823
aS'weight'
p2824
aS'undetectable'
p2825
aS'HBsAg antigen'
p2826
aS'considered statistically significant'
p2827
aS'present formulation Phase'
p2828
aS'temperature 39'
p2829
aS'antibodies Thus most'
p2830
aS'moderate and severe'
p2831
aS'licensed nasal vaccine'
p2832
aS'moderate symptom bothersome'
p2833
aS'20 of healthy'
p2834
aS'volunteers Written'
p2835
aS'Drug Administration'
p2836
aS'permanent disability'
p2837
aS'low responders anti'
p2838
aS'toxicological studies'
p2839
aS'vomiting diarrhea'
p2840
aS'29'
p2841
aS'frequently reported'
p2842
aS'months of study'
p2843
aS'Geometric mean anti'
p2844
aS'study one'
p2845
aS'mucosal irritating potential'
p2846
aS'severe Local site'
p2847
aS'age Volunteers were'
p2848
aS'issue'
p2849
aS'transport antigens'
p2850
aS'renal dialysis'
p2851
aS'each treatment'
p2852
aS'patients or chronic'
p2853
aS'According'
p2854
aS'mild symptom present'
p2855
aS'specialized mechanisms'
p2856
aS'Phase II clinical'
p2857
aS'Nine'
p2858
aS'19 included'
p2859
aS'immunity against HBcAg'
p2860
aS'mucosal blood vessel'
p2861
aS'registered Only two'
p2862
aS'phosphate buffer without'
p2863
aS'allocation'
p2864
aS'antigenic'
p2865
aS'single otorhinolaryngologist performed'
p2866
aS'fever were registered'
p2867
aS'studies HBcAg'
p2868
aS'age Volunteers'
p2869
aS'seroprotective antibody'
p2870
aS'currently licensed'
p2871
aS'g purified'
p2872
aS'accession number X02763'
p2873
aS'Recombinant HBcAg'
p2874
aS'Severe reactions'
p2875
aS'major'
p2876
aS'consultations'
p2877
aS'probability'
p2878
aS'resulting HBcAg'
p2879
aS'0 73 provided'
p2880
aS'reacts with solid'
p2881
aS'Quality Control'
p2882
aS'any clinical'
p2883
aS'detection of total'
p2884
aS'two participants completed'
p2885
aS'eight recipients'
p2886
aS'mouth Two applications'
p2887
aS'including antigen'
p2888
aS'trial no formal'
p2889
aS'mixture of 50g'
p2890
aS'HBsAg significantly'
p2891
aS'cell and antibody'
p2892
aS'threatening'
p2893
aS'least'
p2894
aS'changes in animals'
p2895
aS'Dickinson were filled'
p2896
aS'well documented'
p2897
aS'majority'
p2898
aS'compartment'
p2899
aS'9 sterile'
p2900
aS'chills headache muscle'
p2901
aS'participants needed'
p2902
aS'dose and between'
p2903
aS'general reaction'
p2904
aS'react with antibodies'
p2905
aS'approximately 500DC'
p2906
aS'immunogenicity profile'
p2907
aS'undetectable anti HBs'
p2908
aS'immediate'
p2909
aS'basal'
p2910
aS'neutralization'
p2911
aS'strong HBV'
p2912
aS'study support further'
p2913
aS'Food and Drug'
p2914
aS'defects in dendritic'
p2915
aS'Biokit'
p2916
aS'were mostly'
p2917
aS'against hepatitis'
p2918
aS'kind'
p2919
aS'75 By comparison'
p2920
aS'vial'
p2921
aS'30 Thirty days'
p2922
aS'characterized by electron'
p2923
aS'profile under'
p2924
aS'administered by day'
p2925
aS'vaccine and peptide'
p2926
aS'declare'
p2927
aS'antigen sampling including'
p2928
aS'Cuba All'
p2929
aS'CENATOX'
p2930
aS'HBeAg in saliva'
p2931
aS'immunogenicity Preclinical mouse'
p2932
aS'72hours'
p2933
aS'fixed volume'
p2934
aS'Dawley rats revealed'
p2935
aS'fever were'
p2936
aS'period concluded'
p2937
aS'showing antibody levels'
p2938
aS'glycosylated form HBcAg'
p2939
aS'dendritic'
p2940
aS'categorized'
p2941
aS'0038 All'
p2942
aS'assay anti'
p2943
aS'antibodies against'
p2944
aS'C until'
p2945
aS'virus control Recombinant'
p2946
aS'using similar surveillance'
p2947
aS'immunodominant antigen'
p2948
aS'internal'
p2949
aS'Baseline comparability'
p2950
aS'achieved anti HBs'
p2951
aS'after treatment display'
p2952
aS'specific Th cell'
p2953
aS'Written informed consent'
p2954
aS'added'
p2955
aS'severity mild'
p2956
aS'flu vaccine'
p2957
aS'intensity and 98'
p2958
aS'reach'
p2959
aS'developed antibodies against'
p2960
aS'react'
p2961
aS'commercial ultramicroanalytic enzyme'
p2962
aS'73'
p2963
aS'moderate symptom'
p2964
aS'approved'
p2965
aS'recombinant HBcAg particles'
p2966
aS'given 15 minutes'
p2967
aS'trial Nine participants'
p2968
aS'immunomodulatory effect'
p2969
aS'were healthy'
p2970
aS'reported nasal'
p2971
aS'get 25 seroprotection'
p2972
aS'vaccine Heberbiovac'
p2973
aS'Local adverse'
p2974
aS'graded as severe'
p2975
aS'formulation Sterile'
p2976
aS'recipients one'
p2977
aS'emitted fluorescence'
p2978
aS'authors'
p2979
aS'basal surface'
p2980
aS'aches decreased appetite'
p2981
aS'All sera were'
p2982
aS'attention Serious'
p2983
aS'samples were evaluated'
p2984
aS'candidate administered'
p2985
aS'balanced format'
p2986
aS'other commercial anti'
p2987
aS'impact'
p2988
aS'purity superior'
p2989
aS'parameters'
p2990
aS'64 8IU'
p2991
aS'severe symptoms'
p2992
aS'until use'
p2993
aS'any other nasal'
p2994
aS'basic hematological parameters'
p2995
aS'minutes apart All'
p2996
aS'HBs 10IU'
p2997
aS'prior inoculation'
p2998
aS'surface through'
p2999
aS'Thirty'
p3000
aS'immunogenicity of full'
p3001
aS'antigens by nasal'
p3002
aS'Geometric mean'
p3003
aS'event profile'
p3004
aS'assigned arbitrarily'
p3005
aS'instructed to measure'
p3006
aS'human sera'
p3007
aS'closely'
p3008
aS'male adults between'
p3009
aS'were considered hyper'
p3010
aS'anti HBs protective'
p3011
aS'candidate containing'
p3012
aS'evaluated during'
p3013
aS'State Center'
p3014
aS'HBsAg titer Anti'
p3015
aS'only 30'
p3016
aS'HBs ELISA'
p3017
aS'common'
p3018
aS'rhinorrhea nasal'
p3019
aS'administration also'
p3020
aS'subjects reporting adverse'
p3021
aS'residence time'
p3022
aS'both cases'
p3023
aS'vaccines plant derived'
p3024
aS'plasmid containing'
p3025
aS'Enrique'
p3026
aS'very encouraging taking'
p3027
aS'severe Clinically significant'
p3028
aS'nasal bleeding Solicited'
p3029
aS'Neither'
p3030
aS'trial Nine'
p3031
aS'allowed expiration'
p3032
aS'nasal ulceration'
p3033
aS'97 of adverse'
p3034
aS'kits Samples'
p3035
aS'immunization sera'
p3036
aS'77 recorded'
p3037
aS'currently'
p3038
aS'diluted'
p3039
aS'event There'
p3040
aS'immediate adverse'
p3041
aS'g Miacalcin'
p3042
aS'tolerated safe'
p3043
aS'DC Additionally'
p3044
aS'neither clinical'
p3045
aS'outcomes were'
p3046
aS'corroborates previous findings'
p3047
aS'obtaining written'
p3048
aS'products or immunoglobulin'
p3049
aS'other well'
p3050
aS'study entry'
p3051
aS'8IU l All'
p3052
aS'after vaccine administration'
p3053
aS'nostril were'
p3054
aS'sera Only'
p3055
aS'itching anosmia'
p3056
aS'2000 Among'
p3057
aS'peripheral blood'
p3058
aS'were kept'
p3059
aS'HBV specific immune'
p3060
aS'nucleoprotein in trace'
p3061
aS'headache muscle'
p3062
aS'antibody levels 100IU'
p3063
aS'HBs in sera'
p3064
aS'novel hepatitis'
p3065
aS'immunotherapy'
p3066
aS'became'
p3067
aS'severity Binomial'
p3068
aS'80 90'
p3069
aS'toxicology'
p3070
aS'event rate'
p3071
aS'study products'
p3072
aS'arbitrarily'
p3073
aS'point'
p3074
aS'order to increase'
p3075
aS'protective anti'
p3076
aS'congestion'
p3077
aS'recorded during 90'
p3078
aS'patient with high'
p3079
aS'were reported during'
p3080
aS'populations known'
p3081
aS'high mucosal nasal'
p3082
aS'antibody against'
p3083
aS'multi specific helper'
p3084
aS'vessel'
p3085
aS'candidate formulated'
p3086
aS'rabbits with induction'
p3087
aS'6 months'
p3088
aS'participants received'
p3089
aS'between 24h'
p3090
aS'venipuncture for measurement'
p3091
aS'doctor s visits'
p3092
aS'height between vaccine'
p3093
aS'strategy'
p3094
aS'reduction'
p3095
aS'ensured'
p3096
aS'All anti HBs'
p3097
aS'vaccine recipients according'
p3098
aS'detection of cellular'
p3099
aS'allows interaction'
p3100
aS'annoying'
p3101
aS'abnormalities in clinical'
p3102
aS'one hyper responder'
p3103
aS'trained physician'
p3104
aS'both antigens'
p3105
aS'study in 19'
p3106
aS'Sterile physiologic saline'
p3107
aS'occurred during'
p3108
aS'acemannan Whether'
p3109
aS'liver'
p3110
aS'titers of more'
p3111
aS'Preclinical toxicological'
p3112
aS'developments'
p3113
aS'screening visit'
p3114
aS'highest'
p3115
aS'cause'
p3116
aS'resulting'
p3117
aS'solid'
p3118
aS'safe and immunogenic'
p3119
aS'enrollment'
p3120
aS'coated with commercial'
p3121
aS'well known'
p3122
aS'vaccine allocation'
p3123
aS'antibody tests against'
p3124
aS'behavior'
p3125
aS'Exposure'
p3126
aS'resolving within 72h'
p3127
aS'Becton Dickinson were'
p3128
aS'Furthermore local'
p3129
aS'nurse sprayed'
p3130
aS'37'
p3131
aS'subjects signed'
p3132
aS'volunteers were aware'
p3133
aS'binding'
p3134
aS'study after'
p3135
aS'production facilities'
p3136
aS'display strong'
p3137
aS'immunomodulatory'
p3138
aS'during 90'
p3139
aS'commonly'
p3140
aS'recipients achieved anti'
p3141
aS'seroprotected vaccine'
p3142
aS'reach 75'
p3143
aS'alone'
p3144
aS'aches'
p3145
aS'rate increased'
p3146
aS'estimate'
p3147
aS'reporting of adverse'
p3148
aS'fashion on code'
p3149
aS'studies were'
p3150
aS'authors thank'
p3151
aS'nausea vomiting diarrhea'
p3152
aS'weak HBV specific'
p3153
aS'negative result'
p3154
aS'conflict'
p3155
aS'influenza nasal'
p3156
aS'g HBsAg mixed'
p3157
aS'7 of them'
p3158
aS'performed periodical examinations'
p3159
aS'Miacalcin'
p3160
aS'nasally parenteral administered'
p3161
aS'48hours on administration'
p3162
aS'conducted in Sprague'
p3163
aS'antibody titers against'
p3164
aS'mild self limiting'
p3165
aS'severe Severe reactions'
p3166
aS'systemic reactions 71'
p3167
aS'HBcAg Individuals were'
p3168
aS'did not increase'
p3169
aS'older'
p3170
aS'percentages'
p3171
aS'negative for HBsAg'
p3172
aS'responder volunteer'
p3173
aS'sera Briefly UMELISA'
p3174
aS'clinically significant'
p3175
aS'achieved antibody'
p3176
aS'polyclonal'
p3177
aS'anti HBs 100IU'
p3178
aS'negative immunomodulatory'
p3179
aS'entry'
p3180
aS'clearance'
p3181
aS'Quality'
p3182
aS'adverse events 58'
p3183
aS'carrier state'
p3184
aS'nucleoprotein'
p3185
aS'test for proportions'
p3186
aS'CECMED'
p3187
aS'administered using'
p3188
aS'given 15'
p3189
aS'sera were available'
p3190
aS'devices and methodologies'
p3191
aS'competitive'
p3192
aS'cells transport antigens'
p3193
aS'administration enables antigens'
p3194
aS'against HBsAg 10IU'
p3195
aS'rate exceeded'
p3196
aS'useful'
p3197
aS'recombinant HBsAg subtype'
p3198
aS'Written informed'
p3199
aS'immunoenzymatic assay'
p3200
aS'HBs ELISA kits'
p3201
aS'nasal route showing'
p3202
aS'schedule Following'
p3203
aS'corroborates'
p3204
aS'added reacting'
p3205
aS'specific immune response'
p3206
aS'g of HBcAg'
p3207
aS'12h post immunization'
p3208
aS'estimate each'
p3209
aS'same volume'
p3210
aS'immediate adverse events'
p3211
aS'increase in frequency'
p3212
aS'transparent liquid'
p3213
aS'doses Local adverse'
p3214
aS'liver failure'
p3215
aS'format'
p3216
aS'situation'
p3217
aS'included fever chills'
p3218
aS'HBcAg nucleic acids'
p3219
aS'support further'
p3220
aS'Finlay Hospital Havana'
p3221
aS'showing antibody'
p3222
aS'purified recombinant full'
p3223
aS'0 05'
p3224
aS'allocated to placebo'
p3225
aS'13 excess over'
p3226
aS'diseases immunosuppressive'
p3227
aS'reacting'
p3228
aS'adjustments were made'
p3229
aS'respect to anti'
p3230
aS'signal'
p3231
aS'hospitalizations were also'
p3232
aS'only comprises'
p3233
aS'reported in recipients'
p3234
aS'developed anti'
p3235
aS'over nasally parenteral'
p3236
aS'primary APCs'
p3237
aS'allocation All aspects'
p3238
aS'conducted to characterize'
p3239
aS'Serious adverse'
p3240
aS'low responders'
p3241
aS'nausea vomiting'
p3242
aS'Dawley'
p3243
aS'steroid anti'
p3244
aS'controlled double blinded'
p3245
aS'normal functioning may'
p3246
aS'neutralization using'
p3247
aS'delivered'
p3248
aS'reconstituted'
p3249
aS'rates of seroprotection'
p3250
aS'incubated with samples'
p3251
aS'interest to declare'
p3252
aS'fatal or life'
p3253
aS'nasal bleeding'
p3254
aS'particle to more'
p3255
aS'derived vaccines'
p3256
aS'immunization Withdrawal'
p3257
aS'any immediate'
p3258
aS'nose'
p3259
aS'hyper responder volunteer'
p3260
aS'patient'
p3261
aS'fifth vaccine dose'
p3262
aS'dose at time'
p3263
aS'matched pre'
p3264
aS'treatment display strong'
p3265
aS'vaccine and placebo'
p3266
aS'Dickinson Depending'
p3267
aS'helper and cytotoxic'
p3268
aS'reasonably immunogenic'
p3269
aS'Chronic HBV'
p3270
aS'hepatitis B surface'
p3271
aS'saliva from one'
p3272
aS'body system Adverse'
p3273
aS'after inoculation'
p3274
aS'apparent abnormalities'
p3275
aS'range'
p3276
aS'male adult'
p3277
aS'4 C until'
p3278
aS'remaining 19'
p3279
aS'successive vaccine'
p3280
aS'immunization for any'
p3281
aS'comparison licensed HBV'
p3282
aS'annoying may'
p3283
aS'anti HBs 10IU'
p3284
aS'assay for qualitative'
p3285
aS'candidate developed'
p3286
aS'formal sample'
p3287
aS'antigen uptake'
p3288
aS'Only two moderate'
p3289
aS'recent exposure'
p3290
aS'all participants prior'
p3291
aS'reactions 71'
p3292
aS'enhancement of antiviral'
p3293
aS'computer'
p3294
aS'luminal'
p3295
aS'long'
p3296
aS'after obtaining'
p3297
aS'hepatocellular carcinoma'
p3298
aS'there were'
p3299
aS'time 37'
p3300
aS'result On completion'
p3301
aS'general reaction category'
p3302
aS'self limited'
p3303
aS'two moderate'
p3304
aS'nor induced'
p3305
aS'virus after'
p3306
aS'registered'
p3307
aS'19 participants were'
p3308
aS'X02763 HBsAg'
p3309
aS'Severe'
p3310
aS'calcitonin salmon'
p3311
aS'injection'
p3312
aS'HBs only'
p3313
aS'further immunogenicity'
p3314
aS'group Sneezing palate'
p3315
aS'such as older'
p3316
aS'commonly reported nasal'
p3317
aS'Heberbiovac HB CIGB'
p3318
aS'seroconversion after'
p3319
aS'given via'
p3320
aS'co administered HBsAg'
p3321
aS'criterion for protection'
p3322
aS'increased to 75'
p3323
aS'associated'
p3324
aS'Local site reactions'
p3325
aS'minutes'
p3326
aS'administration of each'
p3327
aS'participants were randomly'
p3328
aS'4 pre existing'
p3329
aS'continuous variables Adverse'
p3330
aS'quantification'
p3331
aS'generated list'
p3332
aS'second vaccine'
p3333
aS'immunosorbent assay ELISA'
p3334
aS'microscopy EM analysis'
p3335
aS'mouse studies'
p3336
aS'carcinoma'
p3337
aS'e g Miacalcin'
p3338
aS'amounts'
p3339
aS'screen failures'
p3340
aS'studied dose'
p3341
aS'over systemic'
p3342
aS'transport'
p3343
aS'visits and hospitalizations'
p3344
aS'gratefully acknowledge'
p3345
aS'HBcAg Individuals'
p3346
aS'fourth immunization Withdrawal'
p3347
aS'positive response'
p3348
aS'most commonly'
p3349
aS'15 participants'
p3350
aS'activity of HBcAg'
p3351
aS'tests 4 pre'
p3352
aS'generated'
p3353
aS'secondary outcomes'
p3354
aS'resulting HBcAg had'
p3355
aS'further assays'
p3356
aS'nucleic acids bound'
p3357
aS'Participants were'
p3358
aS'immunogenic in healthy'
p3359
aS'samples All anti'
p3360
aS'mucosal immune system'
p3361
aS'methodologies'
p3362
aS'fluorescence'
p3363
aS'volumes of samples'
p3364
aS'placebo solution All'
p3365
aS'network of approximately'
p3366
aS'high HBsAg titer'
p3367
aS'recorded adverse events'
p3368
aS'group No unexpected'
p3369
aS'HBs only 30'
p3370
aS'study personnel'
p3371
aS'international'
p3372
aS'developed seroprotective'
p3373
aS'having'
p3374
aS'time of immunization'
p3375
aS'code'
p3376
aS'partial'
p3377
aS'resolving acute'
p3378
aS'group remained positive'
p3379
aS's head'
p3380
aS'existing'
p3381
aS'fourth dose'
p3382
aS'Immunoassay'
p3383
aS'Biotechnology Havana'
p3384
aS'were not substantially'
p3385
aS'third dose'
p3386
aS'mild symptom'
p3387
aS'consultations or doctor'
p3388
aS'mild moderate'
p3389
aS'l per nostril'
p3390
aS'resolving within'
p3391
aS'young'
p3392
aS'between study'
p3393
aS'chronic infection resolving'
p3394
aS'excluded'
p3395
aS'fatal'
p3396
aS'One recipient'
p3397
aS'remained positive'
p3398
aS'adjuvants gene vaccine'
p3399
aS'HBV vaccine Heberbiovac'
p3400
aS'random'
p3401
aS'most frequent'
p3402
aS'group 59'
p3403
aS'vaccine allocation All'
p3404
aS'25 seroprotection'
p3405
aS'venipuncture'
p3406
aS'HBs 10 100IU'
p3407
aS'state of unresponsiveness'
p3408
aS'vaccine and were'
p3409
aS'mucosal immunization further'
p3410
aS'electron'
p3411
aS'cellular'
p3412
aS'functional defects'
p3413
aS'young adults 30'
p3414
aS'cell and cytotoxic'
p3415
aS'100IU l Sera'
p3416
aS'nausea'
p3417
aS'recombinant Heberbiovac HB'
p3418
aS'entire'
p3419
aS'core HBc specific'
p3420
aS'dose of HBsAg'
p3421
aS'induced local damage'
p3422
aS'peripheral blood mononuclear'
p3423
aS'HBsAg subtype CIGB'
p3424
aS'race'
p3425
aS'7 years'
p3426
aS'Adverse events did'
p3427
aS'levels 100IU'
p3428
aS'concluded'
p3429
aS'CIGB production facilities'
p3430
aS'number X02763 HBsAg'
p3431
aS'events as well'
p3432
aS'length recombinant'
p3433
aS'bleeding'
p3434
aS'distressing interference'
p3435
aS'kept under observation'
p3436
aS'responder volunteer generating'
p3437
aS'State'
p3438
aS'included persistently abnormal'
p3439
aS'study No cases'
p3440
aS'surface network'
p3441
aS'transformed previously'
p3442
aS'group sample'
p3443
aS'limiting resolving within'
p3444
aS'anti HBV'
p3445
aS'cutaneous'
p3446
aS'clinical data'
p3447
aS'post immunization Solicited'
p3448
aS'were similar'
p3449
aS'HBV specific'
p3450
aS'consistently'
p3451
aS'code labeled matched'
p3452
aS'white race'
p3453
aS'values'
p3454
aS'hematology values were'
p3455
aS'stuffiness or congestion'
p3456
aS'thin'
p3457
aS'body'
p3458
aS'developed seroprotective antibody'
p3459
aS'doses Adverse'
p3460
aS'status after'
p3461
aS'years range 18'
p3462
aS'other particulate antigens'
p3463
aS'volunteers inoculated'
p3464
aS'strain W3110'
p3465
aS'other symptoms'
p3466
aS'different than'
p3467
aS'functioning may'
p3468
aS'size nine participants'
p3469
aS'vaccine administration'
p3470
aS'consideration'
p3471
aS'any study procedure'
p3472
aS'Participants were kept'
p3473
aS'compromised'
p3474
aS'39'
p3475
aS'38'
p3476
aS'PBMCs'
p3477
aS'involved'
p3478
aS'distribution point'
p3479
aS'fully demonstrated'
p3480
aS'total serum'
p3481
aS'volume of 125'
p3482
aS'vaccines or had'
p3483
aS'vial contained'
p3484
aS'healthy young'
p3485
aS'anti HBs equal'
p3486
aS'examinations'
p3487
aS'formulated'
p3488
aS'all other reactions'
p3489
aS'fluorescent substrate'
p3490
aS'molecule as revealed'
p3491
aS'titer Anti HBs'
p3492
aS'outcomes'
p3493
aS'HBsAg immunogenicity Preclinical'
p3494
aS'comparison with other'
p3495
aS'unresponsiveness'
p3496
aS'sensitivity to any'
p3497
aS'4 pre'
p3498
aS'plant derived'
p3499
aS'each treatment group'
p3500
aS'acute or chronic'
p3501
aS'neither irritating'
p3502
aS'results of preclinical'
p3503
aS'inoculation adverse reactions'
p3504
aS'severe Severe'
p3505
aS'anti inflammatory'
p3506
aS'chemistry and basic'
p3507
aS'duplicate'
p3508
aS'examination'
p3509
aS'days post immunization'
p3510
aS'secondary outcomes were'
p3511
aS'HBcAg CIGB Havana'
p3512
aS'anti inflammatory analgesics'
p3513
aS'first inoculation using'
p3514
aS'10 100IU'
p3515
aS'computer generated'
p3516
aS'Miacalcin nasal'
p3517
aS'occurred'
p3518
aS'transient'
p3519
aS'history of sensitivity'
p3520
aS'rabbit'
p3521
aS'vaccine candidate formulated'
p3522
aS'local reaction'
p3523
aS'nasal conditions'
p3524
aS'randomized and received'
p3525
aS'evident and corroborates'
p3526
aS'animals'
p3527
aS'known nasally'
p3528
aS'immunodominant'
p3529
aS'until use Nasal'
p3530
aS'subtype CIGB'
p3531
aS'Solid phase antigen'
p3532
aS'were closely assessed'
p3533
aS'mucosal blood'
p3534
aS'field'
p3535
aS'positive for anti'
p3536
aS'profile Recent advances'
p3537
aS'Miacalcin nasal spray'
p3538
aS'pre study'
p3539
aS'study drug'
p3540
aS'administered through novel'
p3541
aS'calculation'
p3542
aS'adults and 80'
p3543
aS'proportions'
p3544
aS'symptom present'
p3545
aS'Written'
p3546
aS'anosmia nasal ulceration'
p3547
aS'mononuclear cells PBMCs'
p3548
aS'samples Solid phase'
p3549
aS'particles'
p3550
aS'similar proportion hypo'
p3551
aS'0 2IU'
p3552
aS'doses Adverse events'
p3553
aS'irritating potential'
p3554
aS'during 90 applied'
p3555
aS'vessel status'
p3556
aS'dependent'
p3557
aS'90 day'
p3558
aS'adapted'
p3559
aS'candidate showed'
p3560
aS'using similar'
p3561
aS'hypothesis testing'
p3562
aS'also collected'
p3563
aS'developed anti HBs'
p3564
aS'6ml'
p3565
aS'any local reaction'
p3566
aS'43 subjects'
p3567
aS'discomfort'
p3568
aS'limiting and disappeared'
p3569
aS'without adjuvants'
p3570
aS'any immediate adverse'
p3571
aS'Furthermore participants were'
p3572
aS'recipients as early'
p3573
aS'vaccine doses Adverse'
p3574
aS'binding of HBsAg'
p3575
aS'mice and rabbits'
p3576
aS'study were'
p3577
aS'even without adjuvants'
p3578
aS'One'
p3579
aS'Furthermore participants'
p3580
aS'Nasal administration enables'
p3581
aS'study clearly demonstrates'
p3582
aS'adjustments were'
p3583
aS'competitive sequential'
p3584
aS'Local adverse events'
p3585
aS'abnormalities visualized'
p3586
aS'significant events were'
p3587
aS'preclinical'
p3588
aS'produced'
p3589
aS'including'
p3590
aS'units per liter'
p3591
aS'All reactions were'
p3592
aS'administered by intranasal'
p3593
aS'chemistry'
p3594
aS'white race predominated'
p3595
aS'superior'
p3596
aS'mice with full'
p3597
aS'absent mild symptom'
p3598
aS'consent Individuals'
p3599
aS'reactions combined'
p3600
aS'each rate'
p3601
aS'were self'
p3602
aS'70IU'
p3603
aS'antigen sampling'
p3604
aS'specific active'
p3605
aS'g purified recombinant'
p3606
aS'accession number'
p3607
aS'physicians'
p3608
aS'study nurse sprayed'
p3609
aS'mechanisms'
p3610
aS'assessed by Fisher'
p3611
aS'prophylactic vaccines plant'
p3612
aS'Binomial distribution'
p3613
aS'Solid'
p3614
aS'years range'
p3615
aS'consent and underwent'
p3616
aS'symptom bothersome discomfort'
p3617
aS'functional'
p3618
aS'licensed nasal flu'
p3619
aS'interference with usual'
p3620
aS'two 25'
p3621
aS'study group remained'
p3622
aS'documented'
p3623
aS'high HBsAg'
p3624
aS'predominated over systemic'
p3625
aS'specific active immunotherapy'
p3626
aS'vaccine antigens NASVAC'
p3627
aS'adverse event There'
p3628
aS'route of immunization'
p3629
aS'participants during'
p3630
aS'epistaxis were'
p3631
aS'Biokit Barcelona'
p3632
aS'systemic adverse effects'
p3633
aS'induced serum'
p3634
aS'after immunization'
p3635
aS'determine mucosal irritating'
p3636
aS'blood vessel'
p3637
aS'any adjuvant'
p3638
aS'estimates and 95'
p3639
aS'clinically significant acute'
p3640
aS'core HBc'
p3641
aS'Thirty days'
p3642
aS'cell responses'
p3643
aS'profile under routine'
p3644
aS'Cuba licensed'
p3645
aS'inoculation adverse'
p3646
aS'exceeded'
p3647
aS'80'
p3648
aS'first dose'
p3649
aS'access Furthermore local'
p3650
aS'were given via'
p3651
aS'self limited HBV'
p3652
aS'rez'
p3653
aS'older individuals renal'
p3654
aS'clinical chemistry'
p3655
aS'other well known'
p3656
aS'l seroprotection percentage'
p3657
aS'controlled double'
p3658
aS'include'
p3659
aS'third vaccine dose'
p3660
aS'confirmed in further'
p3661
aS'medical attention Serious'
p3662
aS'formulation and placebo'
p3663
aS'first inoculation Blood'
p3664
aS'solid phase'
p3665
aS'reacts'
p3666
aS'HBV chronically'
p3667
aS'nasal spray device'
p3668
aS'intranasal route'
p3669
aS'serum antibody responses'
p3670
aS'group observation'
p3671
aS'performed however each'
p3672
aS'study procedure'
p3673
aS'70IU l One'
p3674
aS'mean age'
p3675
aS'candidate tested'
p3676
aS'backwards'
p3677
aS'mucosal immune'
p3678
aS'Sprague Dawley rats'
p3679
aS'after obtaining written'
p3680
aS'against HBV infection'
p3681
aS'HBs antibodies'
p3682
aS'e g influenza'
p3683
aS'event There were'
p3684
aS'chills'
p3685
aS'total anti HBc'
p3686
aS'were needed'
p3687
aS'plates 10'
p3688
aS'length HBcAg CIGB'
p3689
aS'sera block antigenic'
p3690
aS'rabbit anti'
p3691
aS'Administration'
p3692
aS'showed seroconversion against'
p3693
aS'spray devices Accuspray'
p3694
aS'58'
p3695
aS'planned medical'
p3696
aS'C terminal region'
p3697
aS'vaccine only comprises'
p3698
aS'mucosal nasal immunogenicity'
p3699
aS'reporting specific'
p3700
aS'promoter'
p3701
aS'antigenicity'
p3702
aS'reactions were defined'
p3703
aS'immunization Solicited adverse'
p3704
aS'systemic immunity elicited'
p3705
aS'discomfort enough'
p3706
aS'adult volunteers'
p3707
aS'antigens to access'
p3708
aS'analgesics non planned'
p3709
aS'0 0038'
p3710
aS'after vaccine'
p3711
aS'report in humans'
p3712
aS'pre existing'
p3713
aS'HBcAg to HBsAg'
p3714
aS'Volunteers were recruited'
p3715
aS'day period'
p3716
aS'1 hour after'
p3717
aS'limitations explained'
p3718
aS'inoculation Adverse events'
p3719
aS'flu vaccine using'
p3720
aS'Novartis'
p3721
aS'placebo developed antibodies'
p3722
aS'obtained by venipuncture'
p3723
aS'screening regarding'
p3724
aS'institution'
p3725
aS'independent antigen'
p3726
aS'blinded study'
p3727
aS'observed'
p3728
aS'vaccine studies HBcAg'
p3729
aS'nasal HBsAg'
p3730
aS'HBcAg nasal vaccine'
p3731
aS'size nine'
p3732
aS'obtained from all'
p3733
aS'any component'
p3734
aS'assays'
p3735
aS'consent Individuals were'
p3736
aS'each subject'
p3737
aS'calcitonin'
p3738
aS'salmon Novartis'
p3739
aS'elicit seroconversion'
p3740
aS'sera Only anti'
p3741
aS'distribution point estimates'
p3742
aS'cells transport'
p3743
aS'phase II'
p3744
aS'clinical studies'
p3745
aS'cytoplasm'
p3746
aS'them were requested'
p3747
aS'apart All'
p3748
aS'5 More'
p3749
aS'protective anti HBs'
p3750
aS'prevent permanent'
p3751
aS'derived vaccines vaccines'
p3752
aS'events included anterior'
p3753
aS'22nm'
p3754
aS'standard parenteral'
p3755
aS'first in human'
p3756
aS'headache both'
p3757
aS'HBcAg nucleic'
p3758
aS'HBcAg combined formulations'
p3759
aS'After'
p3760
aS'titers around 70IU'
p3761
aS'Center Havana Cuba'
p3762
aS'M cell pockets'
p3763
aS'well as hypo'
p3764
aS'chronic diseases'
p3765
aS'candidate were undertaken'
p3766
aS'unresponsiveness characteristic'
p3767
aS'were not available'
p3768
aS'worldwide'
p3769
aS'II clinical'
p3770
aS'injection and up'
p3771
aS'provided to participants'
p3772
aS'II studies'
p3773
aS'dose to achieve'
p3774
aS'inflammatory Th1 response'
p3775
aS'conditions occurred'
p3776
aS'antigens with DC'
p3777
aS'digestive'
p3778
aS'eight'
p3779
aS'posterior nasal dripping'
p3780
aS'nuisance'
p3781
aS'total dose'
p3782
aS'treatment group observation'
p3783
aS'HBsAg exploiting'
p3784
aS'events were tabulated'
p3785
aS'100 of vaccine'
p3786
aS'chronic patients'
p3787
aS'consequences'
p3788
aS'95 purity'
p3789
aS'further phase'
p3790
aS'schedule formulation'
p3791
aS'modulatory effect'
p3792
aS'headache both reports'
p3793
aS'hour after vaccine'
p3794
aS'immunotherapy in HBV'
p3795
aS'available for screening'
p3796
aS'125l per nostril'
p3797
aS'findings'
p3798
aS'comparison licensed'
p3799
aS'0038'
p3800
aS'developments to boost'
p3801
aS'local adverse event'
p3802
aS'negative immunomodulatory effect'
p3803
aS'immunopotentiating'
p3804
aS'participants completed'
p3805
aS'visualized'
p3806
aS'examinations with visualization'
p3807
aS'considered hyper'
p3808
aS'year 2000'
p3809
aS'Briefly anti'
p3810
aS'fourth immunization'
p3811
aS'placebo group Sneezing'
p3812
aS'Organization there'
p3813
aS'pre study screening'
p3814
aS'events between study'
p3815
aS'tolerance All'
p3816
aS'reporting of nasal'
p3817
aS'rash'
p3818
aS'including antigen uptake'
p3819
aS'under routine'
p3820
aS'most moderate symptom'
p3821
aS'vaccine such'
p3822
aS'achieve'
p3823
aS'approximately 500DC mm'
p3824
aS'C until use'
p3825
aS'center randomized placebo'
p3826
aS'peptide'
p3827
aS'28nm'
p3828
aS'g nasal'
p3829
aS'Whether'
p3830
aS'adults in order'
p3831
aS'disappeared within 72hours'
p3832
aS'severe symptoms very'
p3833
aS'were reported more'
p3834
aS'sterile phosphate buffer'
p3835
aS'had clinically significant'
p3836
aS'patients and immune'
p3837
aS'samples Solid'
p3838
aS'vaccine formulation consisting'
p3839
aS'antibody tests'
p3840
aS'given via nasal'
p3841
aS'anti HBc alkaline'
p3842
aS'baseline all'
p3843
aS'strong polyclonal'
p3844
aS'approach'
p3845
aS'assay ELISA'
p3846
aS'exceeded 15'
p3847
aS'samples were collected'
p3848
aS'hyper responder 100IU'
p3849
aS'phosphatase conjugate'
p3850
aS'potent immunogen even'
p3851
aS'fixed'
p3852
aS'site reactions were'
p3853
aS'e g nasal'
p3854
aS'derived recombinant HBsAg'
p3855
aS'study support'
p3856
aS'screening regarding chemical'
p3857
aS'acceptable local'
p3858
aS'humans'
p3859
aS'trace amounts'
p3860
aS'other reactions combined'
p3861
aS'HBsAg in mice'
p3862
aS'clinical adverse'
p3863
aS'display strong polyclonal'
p3864
aS'carriers of hepatitis'
p3865
aS'HBsAg significantly increases'
p3866
aS'sample size calculation'
p3867
aS'B cell'
p3868
aS'days All'
p3869
aS'digestive tract'
p3870
aS'HBV chronic'
p3871
aS'included anterior'
p3872
aS'cytokine response'
p3873
aS'HBs protective'
p3874
aS'investigators'
p3875
aS'any other symptoms'
p3876
aS'routine'
p3877
aS'were measured'
p3878
aS'cells to work'
p3879
aS'bothersome discomfort enough'
p3880
aS'recombinant hepatitis'
p3881
aS'dendritic cell populations'
p3882
aS'electron microscopy'
p3883
aS'size calculation'
p3884
aS'local reaction category'
p3885
aS'emitted'
p3886
aS'disorders or medication'
p3887
aS'immunization nor'
p3888
aS'single nasal'
p3889
aS'anti HBs alkaline'
p3890
aS'hypothesis'
p3891
aS'failure and hepatocellular'
p3892
aS'successive vaccine doses'
p3893
aS'responses against both'
p3894
aS'had no history'
p3895
aS'Also chronic HBV'
p3896
aS'phase II studies'
p3897
aS'nuisance at most'
p3898
aS'Individuals of white'
p3899
aS'parenteral HBV vaccine'
p3900
aS'taking'
p3901
aS'acknowledge'
p3902
aS'both reports'
p3903
aS'EM analysis Further'
p3904
aS'responder 100IU'
p3905
aS'anti HBs UMELISA'
p3906
aS'itching anosmia nasal'
p3907
aS'HBsAg or HBcAg'
p3908
aS'otorhinolaryngologist performed'
p3909
aS'site reactions'
p3910
aS'5 of seroprotected'
p3911
aS'Toxicology and Carlos'
p3912
aS'were estimated'
p3913
aS'animal studies'
p3914
aS'17 and inability'
p3915
aS'candidate demonstrated seroconversion'
p3916
aS'adverse events within'
p3917
aS'include combined prophylactic'
p3918
aS'posterior dripping'
p3919
aS'fact along'
p3920
aS'study clearly'
p3921
aS'Finally'
p3922
aS'administration enables'
p3923
aS'adults Local site'
p3924
aS'seroprotection percentage anti'
p3925
aS'immunity Nasal'
p3926
aS'human clinical trial'
p3927
aS'rates of local'
p3928
aS'methods Concurrent'
p3929
aS'trial were closely'
p3930
aS'one hyper'
p3931
aS'mucosal irritating'
p3932
aS'sequential immunoenzymatic'
p3933
aS'statistical analysis There'
p3934
aS'activator enabling activated'
p3935
aS'years There were'
p3936
aS'kept under'
p3937
aS'3 and epistaxis'
p3938
aS'days following'
p3939
aS'Research Ethics'
p3940
aS'monoclonal'
p3941
aS'muscle aches'
p3942
aS'dripping nasal'
p3943
aS'Drug Quality'
p3944
aS'detection of IgA'
p3945
aS'comprising HBsAg'
p3946
aS'successive reaction'
p3947
aS'sponsor institution Five'
p3948
aS'headache muscle aches'
p3949
aS'decreased'
p3950
aS'labeled matched'
p3951
aS'one month after'
p3952
aS'acute hepatitis'
p3953
aS'virus anti HBs'
p3954
aS'adverse events between'
p3955
aS'secretion of HBeAg'
p3956
aS'multi'
p3957
aS'hepatocellular'
p3958
aS'8 of vaccine'
p3959
aS'reported among individuals'
p3960
aS'statistical analysis'
p3961
aS'spray devices'
p3962
aS'other nasal drug'
p3963
aS'expiration'
p3964
aS'attention or severe'
p3965
aS'preliminary immunogenicity'
p3966
aS'systemic reactions'
p3967
aS'five vaccine doses'
p3968
aS'helper'
p3969
aS'Cuba and 50'
p3970
aS'inoculation using'
p3971
aS'cutaneous rash'
p3972
aS'completed'
p3973
aS'90 applied'
p3974
aS'mucosal adjuvant'
p3975
aS'specific immune'
p3976
aS'interference with normal'
p3977
aS'visualized in vaccine'
p3978
aS'symptoms very distressing'
p3979
aS'dual'
p3980
aS'random numbers'
p3981
aS'Rates of adverse'
p3982
aS'day 30 Thirty'
p3983
aS'Geometric'
p3984
aS'compartment protected'
p3985
aS'prior to any'
p3986
aS'blood screening'
p3987
aS'recording of adverse'
p3988
aS'supported'
p3989
aS'severe Local'
p3990
aS'infrequent Adverse'
p3991
aS'were given 15'
p3992
aS'abnormal baseline'
p3993
aS'units'
p3994
aS'formulations in healthy'
p3995
aS'further phase II'
p3996
aS'group No subjects'
p3997
aS'adults 30 days'
p3998
aS'antibody level'
p3999
aS'around 70IU'
p4000
aS'85 5 More'
p4001
aS'S protein'
p4002
aS'tolerated and reasonably'
p4003
aS'29 7 years'
p4004
aS'revealed neither clinical'
p4005
aS'placebo solution'
p4006
aS'administration of HBcAg'
p4007
aS'sera block'
p4008
aS'reactions were combined'
p4009
aS'international units'
p4010
aS'formulation in each'
p4011
aS'administration comprising'
p4012
aS'center'
p4013
aS'difficult to access'
p4014
aS'fully'
p4015
aS'Conversely'
p4016
aS'were tabulated'
p4017
aS'24h and 72h'
p4018
aS'failures'
p4019
aS'Chronic HBV infection'
p4020
aS'personnel'
p4021
aS'comparisons'
p4022
aS'muscle'
p4023
aS'applied doses 85'
p4024
aS'usual'
p4025
aS'subjects reporting specific'
p4026
aS'Baseline'
p4027
aS'77 adverse events'
p4028
aS'HBsAg HBcAg combined'
p4029
aS'Immunoassay Center Havana'
p4030
aS'recipients of other'
p4031
aS'subjects withdrew'
p4032
aS'salmon'
p4033
aS'HBcAg at day'
p4034
aS'were no differences'
p4035
aS'secreted protein'
p4036
aS'impaired'
p4037
aS'Barcelona Spain'
p4038
aS'inoculations'
p4039
aS'group observation period'
p4040
aS'variables Adverse'
p4041
aS'other licensed nasal'
p4042
aS'devices Accuspray Becton'
p4043
aS'achieved anti'
p4044
aS'10 of adults'
p4045
aS'immunoenhancing activity'
p4046
aS'were considered'
p4047
aS'values were found'
p4048
aS'transparent'
p4049
aS'antiviral therapies'
p4050
aS'reasons'
p4051
aS'potent B cell'
p4052
aS'l One'
p4053
aS'Despite'
p4054
aS'lymphocytes'
p4055
aS'severe Clinically'
p4056
aS'matched'
p4057
aS'decreased appetite nausea'
p4058
aS'inoculation and were'
p4059
aS'closely assessed'
p4060
aS'increased'
p4061
aS'tolerated and induced'
p4062
aS'immunization with hepatitis'
p4063
aS'mild self'
p4064
aS'were aware'
p4065
aS'9 sterile saline'
p4066
aS'increases'
p4067
aS'Food'
p4068
aS'recipients achieved'
p4069
aS'UMELISA plates'
p4070
aS'values were'
p4071
aS'each immunization'
p4072
aS'Further antigenicity'
p4073
aS'three doses'
p4074
aS'significant no adjustments'
p4075
aS'Sneezing palate'
p4076
aS'most moderate'
p4077
aS'mucosal immunogenicity'
p4078
aS'HB CIGB Havana'
p4079
aS'exploiting'
p4080
aS'qualitative'
p4081
aS'considered statistically'
p4082
aS'differences between vaccine'
p4083
aS'hosts'
p4084
aS'l per well'
p4085
aS'days post'
p4086
aS'infection In vaccine'
p4087
aS'Preclinical mouse'
p4088
aS'clearly evident'
p4089
aS'therapeutic'
p4090
aS'products were stored'
p4091
aS'significant persistent'
p4092
aS'hospitalizations'
p4093
aS'placebo received'
p4094
aS'underwent'
p4095
aS'schedule In two'
p4096
aS'balanced format using'
p4097
aS'baseline biochemistry'
p4098
aS'events were mostly'
p4099
aS'Dickinson were'
p4100
aS'effects predominated'
p4101
aS'relevant for virus'
p4102
aS'least one adverse'
p4103
aS'present formulation'
p4104
aS'cell responses against'
p4105
aS'reported nasal adverse'
p4106
aS'chronic carriage'
p4107
aS'monitored'
p4108
aS'consistently demonstrated'
p4109
aS'demonstrates'
p4110
aS'avoid'
p4111
aS'serum clinical'
p4112
aS'presenting cells APCs'
p4113
aS'were filled'
p4114
aS'candidate developed seroprotective'
p4115
aS'18 45'
p4116
aS'HBcAg immunomodulation'
p4117
aS'formulation and device'
p4118
aS'itching palate'
p4119
aS'head tilted backwards'
p4120
aS'bothersome discomfort'
p4121
aS'percentage anti HBc'
p4122
aS'limitations'
p4123
aS'probability of detecting'
p4124
aS'coated'
p4125
aS'used Genbank accession'
p4126
aS'length recombinant HBcAg'
p4127
aS'Center for Drug'
p4128
aS'outpatient basis'
p4129
aS'samples and reagents'
p4130
aS'6 13'
p4131
aS'adverse reaction'
p4132
aS'mucosal immunization'
p4133
aS'other developed anti'
p4134
aS'HBc UMELISA Immunoassay'
p4135
aS'stage'
p4136
aS'adults 30'
p4137
aS'fever chills'
p4138
aS'co purified'
p4139
aS'8 general'
p4140
aS'statistically significant'
p4141
aS'gene vaccine'
p4142
aS'carrier'
p4143
aS'candidate and 10'
p4144
aS'cytokine'
p4145
aS'time day'
p4146
aS'term consequences'
p4147
aS'Also chronic'
p4148
aS'neither irritating nor'
p4149
aS'HBcAg over'
p4150
aS'compromised hosts'
p4151
aS'Sera'
p4152
aS'Two'
p4153
aS'12h post'
p4154
aS'spontaneously and patients'
p4155
aS'nasal conditions occurred'
p4156
aS'device Also chronic'
p4157
aS'test for continuous'
p4158
aS'specialized'
p4159
aS'liquid Each vial'
p4160
aS'Control CECMED'
p4161
aS'immunosorbent assay anti'
p4162
aS'exposure to hepatitis'
p4163
aS'X02763'
p4164
aS'nasally parenteral'
p4165
aS'individuals renal'
p4166
aS'group and one'
p4167
aS'careful performance'
p4168
aS'first vaccine dose'
p4169
aS'Biotechnology Havana Cuba'
p4170
aS'inflammatory Th1'
p4171
aS'exposure'
p4172
aS'recruited'
p4173
aS'71 in recipients'
p4174
aS'transparent liquid Each'
p4175
aS'first hour after'
p4176
aS'range 18'
p4177
aS'interest'
p4178
aS'first dose injection'
p4179
aS'immunogenicity in populations'
p4180
aS'volunteer generating'
p4181
aS'attributed'
p4182
aS'formal hypothesis testing'
p4183
aS'HBV infected patient'
p4184
aS'immunity elicited'
p4185
aS'over nasally'
p4186
aS'Following'
p4187
aS'prevent permanent impairment'
p4188
aS'responses against HBsAg'
p4189
aS'conditions occurred during'
p4190
aS'were fatal'
p4191
aS'administered through'
p4192
aS'recipients according'
p4193
aS'evident'
p4194
aS'immune compromised'
p4195
aS'Ethics Board'
p4196
aS'among individuals'
p4197
aS'signed'
p4198
aS'protein nature'
p4199
aS'wash and saliva'
p4200
aS'carriage'
p4201
aS'sterile saline solution'
p4202
aS'reporting specific post'
p4203
aS'treatment with blood'
p4204
aS'distribution'
p4205
aS'associated with functional'
p4206
aS'formulated with 50'
p4207
aS'display'
p4208
aS'4 9 Only'
p4209
aS'block'
p4210
aS'reported to elicit'
p4211
aS'rabbits'
p4212
aS'showing induction'
p4213
aS'measure'
p4214
aS'generating'
p4215
aS'Thirty days after'
p4216
aS'dose and sera'
p4217
aS'treatment group sample'
p4218
aS'were randomized'
p4219
aS'used as placebo'
p4220
aS'hematological'
p4221
aS'nasal vaccines currently'
p4222
aS'achieved antibody levels'
p4223
aS'CIGB production'
p4224
aS'attention Serious adverse'
p4225
aS'Briefly anti HBs'
p4226
aS'detect differences between'
p4227
aS'l seroprotection'
p4228
aS'43'
p4229
aS'volunteers without'
p4230
aS'anti HBs only'
p4231
aS'subjects showing antibody'
p4232
aS'Five'
p4233
aS'helpful'
p4234
aS'normal'
p4235
aS'individuals renal dialysis'
p4236
aS'30 one'
p4237
aS'6 13 excess'
p4238
aS'formulation Phase'
p4239
aS'15 minutes'
p4240
aS'body system'
p4241
aS'field of devices'
p4242
aS'had not achieved'
p4243
aS'infection Conversely'
p4244
aS'7 days post'
p4245
aS'primary outcome'
p4246
aS'screen failures included'
p4247
aS'recognize any local'
p4248
aS'adverse effects predominated'
p4249
aS'factors'
p4250
aS'persistent'
p4251
aS'minutes apart'
p4252
aS'B surface'
p4253
aS'HBs antibody were'
p4254
aS'analysis There'
p4255
aS'volumes'
p4256
aS'one subject'
p4257
aS'nasal immunogenicity'
p4258
aS'each rate percentages'
p4259
aS'infection or immunization'
p4260
aS'T cell immune'
p4261
aS'cell immune'
p4262
aS'responsiveness'
p4263
aS'major HBV antigens'
p4264
as.